ImmuCell (ICCC) 10-Q13 Nov 242024 Q3 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2024	Oct. 30, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Entity Information [Line Items]
Entity Registrant Name	IMMUCELL CORP /DE/
Entity Central Index Key	0000811641
Entity File Number	001-12934
Entity Tax Identification Number	01-0382980
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	56 Evergreen Drive
Entity Address, City or Town	Portland
Entity Address, State or Province	ME
Entity Address, Postal Zip Code	04103
Entity Phone Fax Numbers [Line Items]
City Area Code	(207)
Local Phone Number	878-2770
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, $0.10 par value per share
Trading Symbol	ICCC
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		8,911,589

Balance Sheets (Unaudited)

Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 3,808,633	$ 978,741
Trade accounts receivable	2,307,913	2,185,383
Inventory	7,460,452	7,811,841
Prepaid expenses and other current assets	310,488	493,885
Total current assets	13,887,486	11,469,850
Property, plant and equipment, net	25,820,333	27,575,683
Operating lease right-of-use asset	4,592,718	4,571,149
Goodwill	95,557	95,557
Intangible assets, net	23,880	38,208
Other assets	28,899	57,655
TOTAL ASSETS	44,448,873	43,808,102
CURRENT LIABILITIES:
Current portion of debt obligations	1,479,058	1,428,807
Current portion of operating lease liability	482,244	644,276
Accounts payable and accrued expenses	2,504,535	2,124,337
Total current liabilities	4,465,837	4,197,420
LONG-TERM LIABILITIES:
Debt obligations, net of current portion	9,422,961	10,540,496
Operating lease liability, net of current portion	4,148,404	4,077,109
Total long-term liabilities	13,571,365	14,617,605
TOTAL LIABILITIES	18,037,202	18,815,025
CONTINGENT LIABILITIES AND COMMITMENTS (See Note 11)
STOCKHOLDER’ EQUITY:
Common stock, $0.10 par value per share, 15,000,000 and 15,000,000 shares authorized, 8,896,398 and 7,814,165 shares issued and 8,833,097 and 7,750,864 shares outstanding, as of September 30, 2024 and December 31, 2023, respectively.	889,641	781,417
Additional paid-in capital	40,338,793	36,357,239
Accumulated deficit	(14,678,281)	(12,007,097)
Treasury stock, at cost, 63,301 shares as of both September 30, 2024 and December 31, 2023	(138,482)	(138,482)
TOTAL STOCKHOLDERS’ EQUITY	26,411,671	24,993,077
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 44,448,873	$ 43,808,102

Balance Sheets (Unaudited) (Par

Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.1	$ 0.1
Common stock, shares authorized	15,000,000	15,000,000
Common stock, shares issued	8,896,398	7,814,165
Common stock, shares outstanding	8,833,097	7,750,864
Treasury stock	63,301	63,301

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
Statements of Operations (Unaudited) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Product sales	$ 6,011,573	$ 5,396,500	$ 18,742,040	$ 12,375,708
Costs of goods sold	4,428,019	4,129,619	13,632,642	9,764,164
Gross margin	1,583,554	1,266,881	5,109,398	2,611,544
Product development expenses	786,136	1,118,489	3,079,189	3,328,397
Sales and marketing expenses	844,045	817,486	2,629,925	2,416,701
Administrative expenses	528,267	514,952	1,661,838	1,611,026
Operating expenses	2,158,448	2,450,927	7,370,952	7,356,124
NET OPERATING LOSS	(574,894)	(1,184,046)	(2,261,554)	(4,744,580)
Other expenses (income), net	125,456	(244,275)	405,610	(113,092)
LOSS BEFORE INCOME TAXES	(700,350)	(939,771)	(2,667,164)	(4,631,488)
Income tax expense	1,340	229	4,020	3,279
NET LOSS	$ (701,690)	$ (940,000)	$ (2,671,184)	$ (4,634,767)
Basic weighted average common shares outstanding (in Shares)	8,164,423	7,746,864	7,908,425	7,746,864
Basic net loss per share (in Dollars per share)	$ (0.09)	$ (0.12)	$ (0.34)	$ (0.6)
Diluted weighted average common shares outstanding (in Shares)	8,164,423	7,746,864	7,908,425	7,746,864
Diluted net loss per share (in Dollars per share)	$ (0.09)	$ (0.12)	$ (0.34)	$ (0.6)

Statements of Stockholders_ Equ

Statements of Stockholders’ Equity (Unaudited) - USD ($)	Common Stock	Additional paid-in capital	Accumulated Deficit	Treasury Stock	Total
Balance at Dec. 31, 2022	$ 781,417	$ 35,978,364	$ (6,232,499)	$ (147,233)	$ 30,380,049
Balance (in Shares) at Dec. 31, 2022	7,814,165			67,301
Net loss			(4,634,767)		(4,634,767)
Stock-based compensation		268,207			268,207
Balance at Sep. 30, 2023	$ 781,417	36,246,571	(10,867,266)	$ (147,233)	26,013,489
Balance (in Shares) at Sep. 30, 2023	7,814,165			67,301
Balance at Jun. 30, 2023	$ 781,417	36,150,137	(9,927,266)	$ (147,233)	26,857,055
Balance (in Shares) at Jun. 30, 2023	7,814,165			67,301
Net loss			(940,000)		(940,000)
Stock-based compensation		96,434			96,434
Balance at Sep. 30, 2023	$ 781,417	36,246,571	(10,867,266)	$ (147,233)	26,013,489
Balance (in Shares) at Sep. 30, 2023	7,814,165			67,301
Balance at Dec. 31, 2023	$ 781,417	36,357,239	(12,007,097)	$ (138,482)	$ 24,993,077
Balance (in Shares) at Dec. 31, 2023	7,814,165			63,301	7,750,864
Net loss			(2,671,184)		$ (2,671,184)
At-The-Market Offering of common stock, net of offering costs	$ 108,224	3,724,866			$ 3,833,090
At-The-Market Offering of common stock, net of offering costs (in Shares)	1,082,233				1,082,233
Stock-based compensation		256,688			$ 256,688
Balance at Sep. 30, 2024	$ 889,641	40,338,793	(14,678,281)	$ (138,482)	$ 26,411,671
Balance (in Shares) at Sep. 30, 2024	8,896,398			63,301	8,833,097
Balance at Jun. 30, 2024	$ 789,639	36,780,897	(13,976,591)	$ (138,482)	$ 23,455,463
Balance (in Shares) at Jun. 30, 2024	7,896,381			63,301
Net loss			(701,690)		(701,690)
At-The-Market Offering of common stock, net of offering costs	$ 100,002	3,480,339			3,580,341
At-The-Market Offering of common stock, net of offering costs (in Shares)	1,000,017
Stock-based compensation		77,557			77,557
Balance at Sep. 30, 2024	$ 889,641	$ 40,338,793	$ (14,678,281)	$ (138,482)	$ 26,411,671
Balance (in Shares) at Sep. 30, 2024	8,896,398			63,301	8,833,097

Statements of Stockholders_ E_2

Statements of Stockholders’ Equity (Unaudited) (Parentheticals) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Statement of Stockholders' Equity [Abstract]
Offering costs on at-the-market offering of common stock	$ 110,838	$ 275,640

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
Statements of Cash Flows (Unaudited) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,671,184)	$ (4,634,767)
Adjustments to reconcile net loss to net cash provided by (used for) operating activities:
Depreciation	1,999,005	2,027,788
Amortization of intangible assets	14,328	14,328
Amortization of debt issuance costs and debt discounts	31,859	12,525
Stock-based compensation	256,688	268,207
Loss on disposal of property, plant and equipment	14,557	8,099
Non-cash rent (benefit) expense	(112,306)	95,881
Changes in:
Trade accounts receivable	(122,530)	(105,985)
Inventory	351,389	(1,347,124)
Prepaid expenses and other current assets	183,397	(201,211)
Other assets	28,756	6,587
Accounts payable and accrued expenses	386,995	(95,493)
Net cash provided by (used for) operating activities	360,954	(3,951,165)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment	(269,509)	(1,811,169)
Prepaid expenses and other current assets		(115,127)
Proceeds from sale of property, plant and equipment	4,500	2,474
Net cash used for investing activities	(265,009)	(1,923,822)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from debt issuance		3,000,000
Proceeds from At-The-Market Offering, net	3,833,090
Proceeds from line of credit		2,000,000
Line of credit repayments		(2,000,000)
Debt principal repayments	(1,094,106)	(829,015)
Payments of debt issuance costs and debt discounts	(5,037)	(98,098)
Net cash (used for) provided by financing activities	2,733,947	2,072,887
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	2,829,892	(3,802,100)
BEGINNING CASH AND CASH EQUIVALENTS	978,741	5,791,562
ENDING CASH AND CASH EQUIVALENTS	3,808,633	1,989,462
CASH PAID FOR:
Income taxes	5,905	7,205
Interest	404,077	303,752
NON-CASH ACTIVITIES:
Decrease in capital expenditures included in accounts payable and accrued expenses	6,797	56,441
Increase in operating lease right-of-use asset and operating lease liability	$ 103,115	$ 2,090,298

Business Operations

Business Operations	9 Months Ended
Business Operations	Sep. 30, 2024
Business Operations [Abstract]
BUSINESS OPERATIONS	1. BUSINESS OPERATIONS ImmuCell Corporation (the “Company”, “we”, “us”, “our”) was originally incorporated in Maine in 1982 and reincorporated in Delaware in 1987, in conjunction with an initial public offering of common stock. We are an animal health company whose purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. We focus on the two most critical stages of dairy productivity, those being the first 30 days of life and the first 30 days of lactation. Our concentrated colostrum and purified Nisin technologies offer unique animal health solutions during these periods when immunity is at its most vulnerable. As disclosed in Note 17, “Segment Information”, one of our business segments is dedicated to Scours and the other is focused on Mastitis. We manufacture and market the First Defense ® Immediate Immunity™ E. coli Re-Tain ®

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) Basis of Presentation We have prepared the accompanying unaudited financial statements reflecting all adjustments (which are of a normal recurring nature) that are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets Generally Accepted Accounting Principles (GAAP) that we follow to ensure we accurately report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB Accounting Standards Codification (b) Cash and Cash Equivalents We consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities backed by the U.S. government. We hold no cash or cash equivalents in excess of Federal Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor. See Note 3. (c) Trade Accounts Receivable Accounts receivable are carried at the original invoice amount less an estimate made for doubtful collection when applicable. Management determines the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts and other relevant factors. Accounts receivable are considered to be past due if a portion of the receivable balance is outstanding for more than 30 days. Past due accounts receivable are subject to an interest charge. It was not necessary to charge interest on past due accounts during the nine-month periods ended September 30, 2024 or 2023 because the time past due was not significant, and there was no accrual for such interest charges as of September 30, 2024 or December 31, 2023. Accounts receivable are written off when deemed uncollectible. No accounts receivable were written off during the nine-month periods ended September 30, 2024 or 2023. Recoveries of accounts receivable previously written off are recorded as income when received. No such recoveries were recorded during the nine-month periods ended September 30, 2024 or 2023. As of September 30, 2024 and December 31, 2023, we determined that no allowance for doubtful accounts was necessary. See Note 4. (d) Inventory Inventory includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or net realizable value (determined as the estimated selling price in the normal course of business, less reasonably predictable costs of completion, disposal and transportation). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. At each balance sheet date, we evaluate our ending inventories for excess quantities and obsolescence. Inventories that we consider excess or obsolete are written down to estimated net realizable value. Once inventory is written down and a new cost basis is established, it is not written back up. We believe that supplies and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products when feasible. See Note 5. (e) Property, Plant and Equipment, net We depreciate property, plant and equipment on the straight-line method by charges to operations and costs of goods sold in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. The facility we have constructed at 33 Caddie Lane to produce the Nisin Drug Substance (DS) for Re-Tain ® Building 33 First Defense ® Building 175A Building 175B (f) Operating Leases We account for our real estate leases using a right-of-use model, which recognizes that at the date of commencement, a lessee has a financial obligation to make lease payments to the lessor for the right to use the underlying asset during the lease term and recognizes a corresponding right-of-use (ROU) asset related to this right. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the expected lease term. The ROU asset is also adjusted for any lease prepayments made, lease incentives received and initial direct costs incurred. For operating leases with lease payments that fluctuate over the lease term, the total lease costs are recognized on a straight-line basis over the lease term. Our leases, at times, may include options to extend the term of the lease. When it is reasonably certain that we will exercise the option, we include the impact of the option in the lease term for purposes of determining future lease payments. For all underlying classes of assets, we made an accounting policy election to not recognize assets or liabilities for leases with a term of twelve months or less and to account for all components in a lease arrangement as a single combined lease component. Short-term lease payments are recognized on a straight-line basis. Certain of our lease agreements include variable rent payments, consisting primarily of amounts paid to the lessor based on cost or consumption, such as maintenance and real estate taxes. These costs are recognized in the period in which the obligation is incurred. Because our leases do not specify an implicit rate, we use an incremental borrowing rate based on information available at the lease commencement date to determine the present value of the lease payments. We evaluate our ROU asset for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. See Notes 2(h) and 12 for additional information. (g) Intangible Assets and Goodwill We amortize intangible assets on the straight-line method by charges to costs of goods sold in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. We have recorded intangible assets related to customer relationships, non-compete agreements and developed technology, each with defined useful lives. Amounts paid in excess of the fair value of the net assets (including tax attributes) are recorded as goodwill under the acquisition method of accounting. We assess the impairment of intangible assets that have indefinite lives (when applicable) and goodwill (at the reporting unit level) on an annual basis (as of December 31 st No (h) Valuation of Long-Lived Assets We periodically evaluate our long-lived assets, consisting principally of property, plant and equipment, operating lease right-of-use asset and amortizable intangible assets, for potential impairment. In accordance with the applicable accounting guidance for the treatment of long-lived assets, we review the carrying value of our long-lived assets or asset group that is held and used, including intangible assets subject to amortization, for impairment whenever events and circumstances indicate that the carrying value of the assets may not be recoverable. Under the held for use approach, the asset or asset group to be tested for impairment should represent the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. No (i) Fair Value Measurements In determining fair value measurements, we follow the provisions of Codification Topic 820, Fair Value Measurements and Disclosures Level 1 — Pricing inputs are quoted prices available in active markets for identical assets or liabilities as of the measurement date. Level 2 — Pricing inputs are quoted prices for similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 3 — Pricing inputs are unobservable for the assets or liabilities, that is, inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level of an asset or liability within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. We also hold money market accounts in our bank account, which are classified as cash equivalents and measured at fair value. The fair value of these investments is based on their closing published net asset value. We assess the levels of the investments at each measurement date, and transfers between levels are recognized on the actual date of the event or change in circumstances that caused the transfer in accordance with our accounting policy regarding the recognition of transfers between levels of the fair value hierarchy. During the nine-month periods ended September 30, 2024 and 2023, there were no transfers between levels. As of September 30, 2024 and December 31, 2023, our Level 1 assets measured at fair value by quoted prices in active markets consisted of cash and money market accounts. There were no assets or liabilities measured at fair value on a nonrecurring basis as of September 30, 2024 or December 31, 2023. The carrying values of our cash and money market accounts as of September 30, 2024 and December 31, 2023 approximated their fair market values. Due to inflation and the changing interest rate environment, the carrying values of our fixed rate bank debt as of September 30, 2024 and December 31, 2023 differed from their fair market values. These values are reflected in the following tables: As of September 30, 2024 Level 1 Level 2 Level 3 Total Assets: Cash and money market accounts $ 3,808,633 $ — $ — $ 3,808,633 Liabilities: Bank debt $ — $ 9,703,821 $ — $ 9,703,821 As of December 31, 2023 Level 1 Level 2 Level 3 Total Assets: Cash and money market accounts $ 978,741 $ — $ — $ 978,741 Liabilities: Bank debt $ — $ 10,431,817 $ — $ 10,431,817 (j) Concentration of Risk Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table: During the Three-Month During the Nine-Month 2024 2023 2024 2023 Company A 43 % 50 % 44 % 48 % Company B 31 % 29 % 33 % 31 % Trade accounts receivable due from significant customers that amounted to 10% or more of our total trade accounts receivable are detailed in the following table: As of As of Company A 37 % 43 % Company B 34 % 36 % (k) Revenue Recognition We recognize revenue in accordance with Codification Topic 606, Revenue from Contracts with Customers (ASC 606) (l) Expense Recognition We do not incur costs in connection with product sales to customers that are eligible for capitalization. Advertising costs are expensed when incurred, which is generally during the month in which the advertisement is published. All product development expenses are expensed as incurred, as are all related patent costs. We capitalize costs to produce inventory during the production cycle, and these costs are charged to costs of goods sold when the inventory is sold to a customer or is deemed to be in excess or obsolete. (m) Income Taxes We account for income taxes in accordance with Codification Topic 740, Income Taxes Codification Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. With few exceptions, we are no longer subject to income tax examinations by tax authorities for years before 2021. We have evaluated the positions taken on our filed tax returns and have concluded that no uncertain tax positions existed as of September 30, 2024 or December 31, 2023. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 16. (n) Stock-Based Compensation We account for stock-based compensation in accordance with Codification Topic 718, Compensation-Stock Compensation (o) Net Loss Per Common Share Net loss per common share has been computed in accordance with Codification Topic 260-10, Earnings Per Share During the Three-Month During the Nine-Month 2024 2023 2024 2023 Net loss attributable to stockholders $ (701,690 ) $ (940,000 ) $ (2,671,184 ) $ (4,634,767 ) Weighted average common shares outstanding - Basic 8,164,423 7,746,864 7,908,425 7,746,864 Dilutive impact of share-based compensation awards — — — — Weighted average common shares outstanding - Diluted 8,164,423 7,746,864 7,908,425 7,746,864 Net loss per share: Basic $ (0.09 ) $ (0.12 ) $ (0.34 ) $ (0.60 ) Diluted $ (0.09 ) $ (0.12 ) $ (0.34 ) $ (0.60 ) (p) Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ from those estimates and are subject to change in the near term. Changes in estimates are recorded during the period in which they become known. Significant estimates include our valuation of inventory, deferred tax assets and costs of goods sold (q) New Accounting Pronouncements Not Yet Adopted In November of 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, In December of 2023, the FASB issued ASU 2023-09 , Income Taxes (Topic 740): Improvements to Income Tax Disclosures

Cash and Cash Equivalents

Cash and Cash Equivalents	9 Months Ended
Cash and Cash Equivalents	Sep. 30, 2024
Cash and Cash Equivalents [Abstract]
CASH AND CASH EQUIVALENTS	3. CASH AND CASH EQUIVALENTS Cash and cash equivalents amounted to $3,808,633 and $978,741 as of September 30, 2024 and December 31, 2023, respectively. See Note 13.

Trade Accounts Receivable

Trade Accounts Receivable	9 Months Ended
Trade Accounts Receivable	Sep. 30, 2024
Trade Accounts Receivable [Abstract]
TRADE ACCOUNTS RECEIVABLE	4. TRADE ACCOUNTS RECEIVABLE Trade accounts receivable amounted to $2,307,913 and $2,185,383 as of September 30, 2024 and December 31, 2023, respectively. No allowance for bad debt or product returns was recorded as of September 30, 2024 or December 31, 2023. We anticipate no future events or conditions that would impact our ability to collect our accounts receivable. Because of the generally short duration from the balance sheet date to the date of collection, our collection rate is not expected to be significantly impacted by events occurring after the balance sheet date. The trade accounts receivable balances included $35,364 and $42,507 due from a related party as of September 30, 2024 and December 31, 2023, respectively. See Note 18.

Inventory

Inventory	9 Months Ended
Inventory	Sep. 30, 2024
Inventory [Abstract]
INVENTORY	5. INVENTORY Inventory consisted of the following: As of As of Raw materials $ 1,313,766 $ 1,594,028 Work-in-process 6,124,394 5,815,194 Finished goods 22,292 402,619 Total $ 7,460,452 $ 7,811,841 These inventory figures are net of write-offs of scrapped inventory in the amounts of $368,723 and $527,133 during the nine-month period ended September 30, 2024 and the year ended December 31, 2023, respectively, that resulted principally from contamination events and other production process losses

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
Prepaid Expenses and Other Current Assets	Sep. 30, 2024
Prepaid Expenses and Other Current Assets [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	6. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consisted of the following: As of As of Prepaid expenses $ 277,146 $ 454,152 Other receivables 33,342 39,733 Total $ 310,488 $ 493,885

Property, Plant and Equipment,

Property, Plant and Equipment, Net	9 Months Ended
Property, Plant and Equipment, Net	Sep. 30, 2024
Property, Plant and Equipment, Net [Abstract]
PROPERTY, PLANT AND EQUIPMENT, net	7. PROPERTY, PLANT AND EQUIPMENT, net Property, plant and equipment consisted of the following: Estimated Useful Lives As of As of Laboratory and manufacturing equipment 3-10 $ 21,183,888 $ 20,953,601 Buildings and improvements 10-39 20,858,708 20,784,565 Office furniture and equipment 3-10 1,053,436 1,036,374 Construction in progress n/a 2,588,630 2,768,224 Land n/a 516,867 516,867 Property, plant and equipment, gross 46,201,529 46,059,631 Accumulated depreciation (20,381,196 ) (18,483,948 ) Property, plant and equipment, net $ 25,820,333 $ 27,575,683 As of September 30, 2024 and December 31, 2023, construction in progress consisted principally of payments toward the First Defense ® Re-Tain ®

Intangible Assets

Intangible Assets	9 Months Ended
Intangible Assets	Sep. 30, 2024
Intangible Assets [Abstract]
INTANGIBLE ASSETS	8. INTANGIBLE ASSETS Intangible assets of $191,040 were valued using the relief from royalty method and are being amortized to costs of goods sold over their useful lives, which are estimated to be 10 years. Intangible amortization expense was $4,776 during both of the three-month periods ended September 30, 2024 and 2023 and $14,328 during both of the nine-month periods ended September 30, 2024 and 2023. The net value of these intangibles was $23,880 and $38,208 as of September 30, 2024 and December 31, 2023, respectively. Intangible asset amortization expense is estimated to be $19,104 per year through December 31, 2025. Intangible assets as of September 30, 2024 consisted of the following: Gross Carrying Accumulated Net Book Developed technology $ 184,100 $ (161,087 ) $ 23,013 Customer relationships 1,300 (1,138 ) 162 Non-compete agreements 5,640 (4,935 ) 705 Total $ 191,040 $ (167,160 ) $ 23,880 Intangible assets as of December 31, 2023 consisted of the following: Gross Carrying Accumulated Net Book Developed technology $ 184,100 $ (147,280 ) $ 36,820 Customer relationships 1,300 (1,040 ) 260 Non-compete agreements 5,640 (4,512 ) 1,128 Total $ 191,040 $ (152,832 ) $ 38,208

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
Accounts Payable and Accrued Expenses	Sep. 30, 2024
Accounts Payable and Accrued Expenses [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	9. ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consisted of the following: As of As of Accounts payable – trade $ 876,836 $ 874,558 Accounts payable – capital 6,378 13,175 Accrued payroll 1,142,318 942,999 Accrued professional fees 101,725 97,800 Accrued other 376,112 192,754 Income tax payable 1,166 3,051 Total $ 2,504,535 $ 2,124,337

Bank Debt

Bank Debt	9 Months Ended
Bank Debt	Sep. 30, 2024
Bank Debt [Abstract]
BANK DEBT	10. BANK DEBT Loans #1 and #2 Line of Credit (LOC) Loan #3 Loan #4 Loan #5 Loan #6: Loan #7: Loans #1, #2, #4, #6 and #7 are secured by liens on substantially all of our assets and are subject to certain restrictions and financial covenants. Loan #7 is subordinated to Loans #1, #2, #4 and #6. Reflecting our poor financial performance during 2023 and into the first nine months of 2024, the debt service covenant (DSC) requirements for the twelve-month periods ended December 31, 2023, June 30, 2024, September 30, 2024 and December 31, 2024 were waived pre-emptively by our lenders. We are required to meet a minimum DSC ratio of 1.35 for the year ending December 31, 2025 and annually thereafter. In connection with these credit facilities, we incurred aggregate debt issuance and debt discount costs of $173,305 ($5,037 and $0 of which was incurred during the nine-month periods ended September 30, 2024 and 2023, respectively). The amortization of these debt issuance and debt discount costs is being recorded as a component of interest expense, included in other expenses, net, and is being amortized on a straight-line basis over the underlying terms of the notes. Loans #3 and #5 are unsecured and subordinated to our indebtedness to GSB and FAME. Failure to make timely payments of principal and interest, or otherwise to comply with the terms of the agreements of Loans #3 and #5, would entitle the MTI to accelerate the maturity of such debt and demand repayment in full. These loans may be prepaid without penalty at any time. Debt proceeds received and principal repayments made (excluding our $1,000,000 line of credit) are reflected by loan during the periods as described in the tables below: During the Three-Month Period Ended September 30, 2024 During the Three-Month Proceeds from Debt Principal Proceeds from Debt Principal Loan #1 $ — $ 57,671 $ — $ 55,619 Loan #2 — 128,534 — 124,020 Loan #3 — 24,173 — 23,002 Loan #4 — 53,505 — 51,622 Loan #5 — 16,719 — 15,909 Loan #6 — 59,191 2,000,000 36,582 Loan #7 — 28,456 1,000,000 18,983 Total $ — $ 368,249 $ 3,000,000 $ 325,737 During the Nine-Month Period Ended September 30, 2024 During the Nine-Month Period Ended September 30, 2023 Proceeds from Debt Principal Proceeds from Debt Principal Loan #1 $ — $ 172,017 $ — $ 166,527 Loan #2 — 382,324 — 369,154 Loan #3 — 71,629 — 68,156 Loan #4 — 159,171 — 153,704 Loan #5 — 49,542 — 15,909 Loan #6 — 174,804 2,000,000 36,582 Loan #7 — 84,619 1,000,000 18,983 Total $ — $ 1,094,106 $ 3,000,000 $ 829,015 During the Year During the Year Proceeds from Debt Principal Proceeds from Debt Principal Loan #1 $ — $ 223,222 $ 2,000,000 $ 199,013 Loan #2 — 494,455 — 477,237 Loan #3 — 91,446 — 22,160 Loan #4 — 205,884 — 198,715 Loan #5 — 32,017 — — Loan #6 2,000,000 93,054 — — Loan #7 1,000,000 45,696 — — Total $ 3,000,000 $ 1,185,774 $ 2,000,000 $ 897,125 Principal payments (net of debt issuance and debt discount costs) due under bank loans outstanding as of September 30, 2024 (excluding our $1,000,000 line of credit) are reflected in the following table by the year that payments are due: During the During the Years Ending December 31, 2024 2025 2026 2027 2028 Thereafter Total Loan #1 $ 58,765 $ 239,876 $ 248,604 $ 257,649 $ 266,537 $ 4,598,457 $ 5,669,888 Loan #2 129,801 530,738 549,881 140,436 — — 1,350,856 Loan #3 24,476 101,000 106,146 83,143 — — 314,765 Loan #4 54,055 220,994 228,965 240,442 — — 744,456 Loan #5 16,929 69,856 73,415 77,156 81,086 — 318,442 Loan #6 60,581 253,003 1,418,558 — — — 1,732,142 Loan #7 29,617 124,364 715,704 — — — 869,685 Subtotal 374,224 1,539,831 3,341,273 798,826 347,623 4,598,457 11,000,234 Debt issuance cost (5,583 ) (21,314 ) (13,580 ) (5,420 ) (3,513 ) (11,347 ) (60,757 ) Debt discount cost (5,223 ) (20,891 ) (11,344 ) — — — (37,458 ) Total $ 363,418 $ 1,497,626 $ 3,316,349 $ 793,406 $ 344,110 $ 4,587,110 $ 10,902,019

Contingent Liabilities and Comm

Contingent Liabilities and Commitments	9 Months Ended
Contingent Liabilities and Commitments	Sep. 30, 2024
Contingent Liabilities and Commitments [Abstract]
CONTINGENT LIABILITIES AND COMMITMENTS	11. CONTINGENT LIABILITIES AND COMMITMENTS Our bylaws, as amended, in effect provide that the Company will indemnify its officers and directors against any liability arising from their responsibilities as officers and directors to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings with each director through a separate indemnification agreement with that director. The maximum payment that we may be required to make under such provisions is theoretically unlimited and is impossible to determine. We maintain directors’ and officers’ liability insurance, which may provide reimbursement to the Company for payments made to, or on behalf of, officers and directors pursuant to the indemnification provisions. Our indemnification obligations were grandfathered under the provisions of Codification Topic 460 , Guarantees The development, manufacturing and marketing of animal health care products entails an inherent risk that liability claims will be asserted against us during the normal course of business. We are aware of no such claims against us as of the date of this filing. We believe that we have reasonable levels of liability insurance to support our operations. We enter into agreements with third parties in the ordinary course of business under which we are obligated to indemnify such third parties from and against various risks and losses. The precise terms of such indemnities vary with the nature of the agreement. In many cases, we limit the maximum amount of our indemnification obligations, but in some cases those obligations may be theoretically unlimited. We have not incurred material expenses in discharging any of these indemnification obligations and based on our analysis of the nature of the risks involved, we believe that the fair value of the liabilities potentially arising under these agreements is minimal. Accordingly, we recorded no liabilities for such obligations as of September 30, 2024 or December 31, 2023. We plan to purchase certain key parts (syringes) and services (formulation, aseptic filling and final packaging) pertaining to Re-Tain ® Effective March 28, 2022, we entered into an Amended and Restated Separation and Deferred Compensation Agreement (the “Deferred Compensation Agreement”) with Mr. Brigham (our President and CEO) that superseded and replaced in its entirety a March 2020 severance agreement between the Company and Mr. Brigham. Upon separation from the Company for any reason, Mr. Brigham’s Deferred Compensation Agreement allows Mr. Brigham to be paid, among other amounts, all earned and unused paid time off (which expense totaling $222,379 was accrued during the first quarter of 2022 and $230,162 was included in accounts payable and accrued expenses on the accompanying balance sheets as of both September 30, 2024 and December 31, 2023) and to receive up to an additional $300,000 in deferred compensation (which amount is being accrued over the three-year period ending in January 2025). This deferred compensation payment vested as to $100,000 on January 1, 2023 and an additional $100,000 on January 1, 2024. An additional $100,000 will vest on January 1, 2025, provided that Mr. Brigham is employed by the Company as of such date. The vested amounts would be paid upon the earlier of January 31, 2025 or within thirty (30) days following his separation from the Company. As of September 30, 2024 and December 31, 2023, $275,000 and $200,000, respectively, was included in accounts payable and accrued expenses on the accompanying balance sheets. In addition, upon termination of Mr. Brigham’s employment (a) by the Company other than for cause, (b) due to death or disability or (c) by Mr. Brigham for good reason, in each case as described and defined in the Deferred Compensation Agreement, the Company agrees to pay Mr. Brigham 100% of his then current annual base salary and a lump sum payment equal to the employer portion of the costs of continued health benefits for Mr. Brigham and his covered dependents for a twelve-month period following termination, and certain equity incentive awards granted to Mr. Brigham would continue to vest following such termination in accordance with the terms of the Deferred Compensation Agreement. Incentive compensation agreements may be entered into with Mr. Brigham, Ms. Brockmann (our Vice President of Sales and Marketing) and Ms. Williams (our Vice President of Manufacturing Operations) which, at times, allow these executives to earn incentive compensation if certain regulatory and financial objectives are met during the year to which the agreement relates, as specified in their agreements. Amounts related to these incentive compensation agreements are accrued over the period they are earned (when it is probable that the amounts will be earned) based on our best estimate of the amounts expected to be In addition to the commitments discussed above, we had committed $186,000 to increase our production capacity for the First Defense ® Re-Tain ®

Operating Lease

Operating Lease	9 Months Ended
Operating Lease	Sep. 30, 2024
Operating Lease [Abstract]
OPERATING LEASE	12. OPERATING LEASE On September 12, 2019, we entered into a lease covering approximately 14,300 square feet of office and warehouse space with a possession date of November 15, 2019 and a commencement date of February 13, 2020. The property is located at 175 Industrial Way in Portland ( Building 175A First Defense ® Building 175B Building 175B Building 175B, Building 175A Building 175B During the Three-Month During the Nine-Month 2024 2023 2024 2023 Lease Cost Operating lease cost $ 106,880 $ 98,714 $ 320,639 $ 244,954 Variable lease cost 21,486 9,720 50,638 27,054 Total lease cost $ 128,366 $ 108,434 $ 371,277 $ 272,008 Operating Lease Cash paid for operating lease liabilities $ 144,315 $ 69,742 $ 432,945 $ 131,476 Weighted average remaining lease term (in years) 18.3 19.3 18.3 19.3 Weighted average discount rate 6.6 % 6.3 % 6.6 % 6.3 % Future lease payments required under non-cancelable operating leases in effect as of September 30, 2024 were as follows: Amount During the three-month period ending December 31, 2024 $ 144,315 During the years ending December 31, 2025 711,623 2026 349,744 2027 356,732 2028 363,870 Thereafter 5,949,488 Total lease payments (undiscounted cash flows) 7,875,772 Less: imputed interest (discount effect of cash flows) (3,245,124 ) Total operating liabilities $ 4,630,648

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
Stockholders’ Equity	Sep. 30, 2024
Stockholders’ Equity [Abstract]
STOCKHOLDERS’ EQUITY	13. STOCKHOLDERS’ EQUITY Common Stock Issuances From February of 2016 to April of 2021, we sold the aggregate of 4,553,017 shares of common stock in six different transactions raising gross proceeds of $26,714,403 at the weighted average price of $5.87 per share. These funds have been essential to funding our business growth plans. The details of each transaction are discussed below: 1) During February of 2016, we sold 1,123,810 shares of common stock at a price to the public of $5.25 per share in an underwritten public offering pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $5,900,003 and resulting in net proceeds to the Company of $5,313,224 (after deducting underwriting discounts and offering expenses incurred in connection with the equity financing). 2) During October of 2016, we sold, in a private placement, 659,880 shares of common stock to nineteen institutional and accredited investors at $5.25 per share, raising gross proceeds of $3,464,370 and resulting in net proceeds to the Company of $3,160,923 (after deducting placement agent fees and other expenses incurred in connection with the equity financing). 3) During July of 2017, we sold 200,000 shares of our common stock at a price of $5.25 per share in a public, registered sale to two related investors pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $1,050,000 and resulting in net proceeds of $1,034,164 (after deducting expenses incurred in connection with the equity financing). 4) During December of 2017, we sold 417,807 shares of common stock at a price to the public of $7.30 per share in an underwritten public offering pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $3,049,991 and resulting in net proceeds to the Company of $2,734,173 (after deducting underwriting discounts and offering expenses incurred in connection with the equity financing). 5) During March of 2019, we sold 1,636,364 shares of common stock at a price to the public of $5.50 per share in an underwritten public offering pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $9,000,002 and resulting in net proceeds to the Company of $8,303,436 (after deducting underwriting discounts and offering expenses incurred in connection with the equity financing). 6) During April of 2021, we sold 515,156 shares of our common stock at a price of $8.25 per share in a public, registered sale to seven investors pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $4,250,038 and resulting in net proceeds of $4,233,026 (after deducting expenses incurred in connection with the equity financing). At-The-Market Offering On April 9, 2024, our shelf registration on Form S-3 (File No. 333-278438) relating to the offer, issuance and sale by the Company of up to $20,000,000 of securities was declared effective by the Securities and Exchange Commission. Also on April 9, 2024, we entered into an At-The-Market Agreement (ATM Agreement) with Craig-Hallum Capital Group LLC, pursuant to which we may offer and sell up to $11,000,000 of shares of our common stock. Legal, accounting and other fees in the amount of $152,272 associated with the completion of the shelf registration and the ATM Agreement were initially capitalized and then were offset against the initial proceeds received during the second quarter of 2024. As of September 30, 2024, we had sold 1,082,233 shares under the at the market offering conducted pursuant to the ATM Agreement. Net proceeds through September 30, 2024 from shares sold pursuant to the ATM Agreement (net of the upfront legal, accounting and other fees), less sales commissions of $123,368, were $3,833,090. Stock Option Plans In June of 2010, our stockholders approved the 2010 Stock Option and Incentive Plan (the “2010 Plan”) pursuant to the provisions of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of the Company’s common stock at no less than fair market value on the date of grant. At that time, 300,000 shares of common stock were reserved for issuance under the 2010 Plan and subsequently no additional shares have been reserved for the 2010 Plan. Vesting requirements are determined by the Compensation and Stock Option Committee of the Board of Directors on a case-by-case basis. All options granted under the 2010 Plan expire no later than 10 years from the date of grant. The 2010 Plan expired in June of 2020, after which date no further options can be granted under the 2010 Plan. However, options outstanding under the 2010 Plan at that time can be exercised in accordance with their terms. There were 183,500 and 188,500 options outstanding under the 2010 Plan as of September 30, 2024 and December 31, 2023, respectively. In June of 2017, our stockholders approved the 2017 Stock Option and Incentive Plan (the “2017 Plan”) pursuant to the provisions of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of the Company’s common stock at no less than fair market value on the date of grant. At that time, 300,000 shares of common stock were reserved for issuance under the 2017 Plan. An amendment to the 2017 Plan increasing the number of shares reserved for issuance under the 2017 Plan from 300,000 shares to 650,000 shares was approved by a vote of stockholders at the Annual Meeting of Stockholders in June of 2022. Vesting requirements are determined by the Compensation and Stock Option Committee of the Board of Directors on a case-by-case basis. All options granted under the 2017 Plan expire no later than 10 years from the date of grant. The 2017 Plan expires in March of 2027, after which date no further options can be granted under the 2017 Plan. However, options outstanding under the 2017 Plan at that time can be exercised in accordance with their terms. As of September 30, 2024 and December 31, 2023, there were 477,500 and 430,000 options outstanding under the 2017 Plan, respectively. Activity under the stock option plans described above was as follows: 2010 Plan 2017 Plan Weighted Average Exercise Price Aggregate Intrinsic Value (1) Outstanding as of December 31, 2022 202,500 402,500 $ 7.19 $ (661,310 ) Grants — 122,000 $ 5.16 Terminations/forfeitures (2) (10,000 ) (94,500 ) $ 7.12 Exercises (4,000 ) — $ 4.69 Outstanding as of December 31, 2023 188,500 430,000 $ 6.82 $ (1,071,121 ) Grants — 73,000 $ 3.80 Terminations/forfeitures (2) (5,000 ) (25,500 ) $ 6.75 Exercises — — $ — Outstanding as of September 30, 2024 183,500 477,500 $ 6.49 $ (1,891,421 ) Vested as of September 30, 2024 183,500 136,500 $ 6.97 $ (1,068,740 ) Vested and expected to vest as of September 30, 2024 183,500 477,500 $ 6.49 $ (1,891,421 ) Reserved for future grants — 154,500 (1) Intrinsic value is the difference between the fair market value of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise price). (2) Terminations and forfeitures are recognized when they occur. The following table displays additional information about the stock option plans described above: Number of Shares Weighted Average Weighted Average Exercise Price Non-vested stock options as of December 31, 2023 337,500 $ 3.66 $ 7.14 Non-vested stock options as of September 30, 2024 341,000 $ 3.14 $ 6.04 Stock options granted during the nine-month period ended September 30, 2024 73,000 $ 1.72 $ 3.80 Stock options that vested during the nine-month period ended September 30, 2024 54,000 $ 4.31 $ 9.73 Stock options that were terminated or forfeited during the nine-month period ended September 30, 2024 30,500 $ 3.36 $ 6.75 No stock options were exercised during the three-month or nine-month periods ended September 30, 2024 and 2023. The weighted average remaining life of the options outstanding under the 2010 Plan and the 2017 Plan as of September 30, 2024 was approximately 5 years. The weighted average remaining life of the options exercisable under these plans as of September 30, 2024 was approximately 2 years and 11 months. The exercise price of the options outstanding under these plans as of September 30, 2024, ranged from $3.60 to $10.04 per share. The 73,000 stock options granted during the nine-month period ended September 30, 2024 had an average exercise price of $3.80 per share. The 108,000 stock options granted during the nine-month period ended September 30, 2023 had an average exercise price of $5.19 per share. The weighted-average grant date fair values of options granted during the nine-month periods ended September 30, 2024 and 2023 were $1.72 and $2.80 per share, respectively. As of September 30, 2024, total unrecognized stock-based compensation related to non-vested stock options aggregated $433,317 which will be recognized over a weighted average remaining period of approximately 1 year and 5 months. The fair value of each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the following weighted-average assumptions: During the Three-Month During the Nine-Month 2024 2023 2024 2023 Risk-free interest rate (1) 3.48 % n/a (4) 3.70 % 3.48 % Dividend yield (2) 0 % 0 % 0 % 0 % Expected volatility (2) 52 % n/a (4) 51 % 54 % Expected life (3) 4.1 years n/a (4) 4.3 years 6.2 years (1) The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected option term. (2) The dividend yield and expected volatility are derived from averages of our historical data. (3) The expected life is calculated utilizing the simplified method, which uses the mid-point between the vesting period and the contractual term as the expected life. (4) These values are not applicable because no Common Stock Rights Plan In September of 1995, our Board of Directors adopted a Common Stock Rights Plan (the “Rights Plan”) and declared a dividend of one common share purchase right (a “Right”) for each of the then outstanding shares of the common stock of the Company. Each Right entitles the registered holder to purchase from the Company one share of common stock at an initial purchase price of $70.00 per share, subject to adjustment. The description and terms of the Rights are set forth in a Rights Agreement between the Company and Equiniti Trust Company, LLC, as Rights Agent. The Rights (as amended) become exercisable and transferable apart from the common stock upon the earlier of i) 10 days following a public announcement that a person or group (Acquiring Person) has, without the prior consent of the Continuing Directors (as such term is defined in the Rights Agreement), acquired beneficial ownership of 20% or more of the outstanding common stock or ii) 10 days following commencement of a tender offer or exchange offer the consummation of which would result in ownership by a person or group of 20% or more of the outstanding common stock (the earlier of such dates being called the Distribution Date). Upon the Distribution Date, the holder of each Right not owned by the Acquiring Person would be entitled to purchase common stock at a discount to the initial purchase price of $70.00 per share, effectively equal to one half of the market price of a share of common stock on the date the Acquiring Person becomes an Acquiring Person. If, after the Distribution Date, the Company should consolidate or merge with any other entity and the Company were not the surviving company, or, if the Company were the surviving company, all or part of the Company’s common stock were changed or exchanged into the securities of any other entity, or if more than 50% of the Company’s assets or earning power were sold, each Right would entitle its holder to purchase, at the Rights’ then-current purchase price, a number of shares of the acquiring company’s common stock having a market value at that time equal to twice the Right’s exercise price. At any time after a person or group becomes an Acquiring Person and prior to the acquisition by such person or group of 50% or more of the outstanding common stock, the Board of Directors of the Company may exchange the Rights (other than Rights owned by such person or group which have become void), in whole or in part, at an exchange ratio of one share of common stock per Right (subject to adjustment). At any time prior to 14 days following the date that any person or group becomes an Acquiring Person (subject to extension by the Board of Directors), the Board of Directors of the Company may redeem the then outstanding Rights in whole, but not in part, at a price of $0.005 per Right, subject to adjustment. During the third quarter of 2011, our Board of Directors voted to authorize an amendment to the Rights Plan to increase the ownership threshold for determining “Acquiring Person” status to 20%. During the second quarter of 2015, our Board of Directors also voted to authorize an amendment to remove a provision that prevented a new group of directors elected following the emergence of an Acquiring Person (an owner of more than 20% of our stock) from controlling the Rights Plan by maintaining exclusive authority over the Rights Plan with pre-existing directors. We did this because such provisions have come to be viewed with disfavor by Delaware courts. Each time that we made such amendments we entered into amendments to the Rights Agreement with the Rights Agent reflecting such extensions, threshold increases or provision changes. No other changes have been made to the terms of the Rights or the Rights Plan. At various times over the years, our Board of Directors, which has the authority to amend the Rights Plan, has voted to authorize amendments to the Rights Plan to extend the expiration date of the Rights Plan. Our Board of Directors decided to seek an advisory vote by stockholders at the Annual Meeting of Stockholders held in June of 2022, as to whether to extend the Rights Plan by one year to September 19, 2023. Of the votes actually cast on this proposal, 65% voted in favor, 32% voted against and 3% abstained. On the basis of this vote, our Board of Directors voted to extend the Rights Plan by one year to September 19, 2023. Our Board of Directors decided to seek another advisory vote by stockholders at the Annual Meeting of Stockholders held in June of 2023, as to whether to extend the Rights Plan by another year to September 19, 2024. Of the votes actually cast on this proposal, 65.10% voted in favor, 34.60% voted against and 0.30% abstained. On the basis of this vote, our Board of Directors voted to extend the Rights Plan by one year to September 19, 2024. Recognizing that there might be a substantial number of broker non-votes, our Board of Directors disclosed that it would be guided by the votes actually cast on these proposals in deciding whether to extend the expiration date of such plan by one year. Our Board of Directors determined not to further extend the Rights Plan because these plans are generally considered not to be stockholder friendly. With no further extension, the Rights Plan expired as of September 19, 2024. Authorized Common Stock At the June 14, 2018 Annual Meeting of Stockholders, our stockholders voted to approve an amendment to our Certificate of Incorporation to increase the number of shares of common stock authorized for issuance from 8,000,000 to 11,000,000. At the June 10, 2020 Annual Meeting of Stockholders, our stockholders voted to approve an amendment to our Certificate of Incorporation to increase the number of shares of common stock authorized for issuance from 11,000,000 to 15,000,000.

Revenue

Revenue	9 Months Ended
Revenue	Sep. 30, 2024
Revenue [Abstract]
REVENUE	14. REVENUE We primarily offer the First Defense Ò product line to dairy and beef producers to prevent scours in newborn calves. Generally, our products are promoted to veterinarians as well as dairy and beef producers by our sales team and then sold through distributors. Our primary market is North America. We do sell into select international regions and may expand this international reach in the future. There were no material changes between the allocation and timing of revenue recognition during the three-month or nine-month periods ended September 30, 2024 or 2023. We do not have any contract assets for which we have satisfied the performance obligations, but do not yet have the right to bill for, or contract liabilities such as customer advances. All trade receivables on our balance sheet are from contracts with customers. We incur no material costs to obtain contracts. The following table presents our product sales disaggregated by geographic area: During the Three-Month During the Nine-Month 2024 % 2023 % 2024 % 2023 % United States $ 5,216,401 87 % $ 4,923,265 91 % $ 16,449,178 88 % $ 11,173,686 90 % Other 795,172 13 % 473,235 9 % 2,292,862 12 % 1,202,022 10 % Total Product Sales $ 6,011,573 100 % $ 5,396,500 100 % $ 18,742,040 100 % $ 12,375,708 100 % The following table presents our product sales disaggregated by major product category: During the Three-Month During the Nine-Month 2024 % 2023 % 2024 % 2023 % First Defense ® product line $ 5,951,344 99 % $ 5,360,063 99 % $ 18,602,053 99 % $ 12,253,555 99 % Other animal health 60,229 1 % 36,437 1 % 139,987 1 % 122,153 1 % Total Product Sales $ 6,011,573 100 % $ 5,396,500 100 % $ 18,742,040 100 % $ 12,375,708 100 %

Other Expenses, Net

Other Expenses, Net	9 Months Ended
Other Expenses, Net	Sep. 30, 2024
Other Expenses, Net [Abstract]
OTHER EXPENSES, NET	15. OTHER EXPENSES, NET Other expenses net, consisted of the following: During the Three-Month During the Nine-Month 2024 2023 2024 2023 Interest expense (1) $ 144,141 $ 144,616 $ 432,529 $ 323,177 Loss (gain) on disposal of property, plant and equipment — (68 ) 14,557 8,099 Interest income (18,685 ) (23,696 ) (41,476 ) (79,134 ) Insurance recoveries (2) — (365,127 ) — (365,127 ) Income - other — — — (107 ) Other expenses (income), net $ 125,456 $ (244,275 ) $ 405,610 $ (113,092 ) (1) Interest expense includes amortization of debt issuance and debt discount costs of $10,805 and $8,687 during the three-month periods ended September 30, 2024 or 2023, respectively, and $31,859 and $12,525 during the nine-month periods ended September 30, 2024 and 2023, respectively. (2) The income from insurance recoveries resulted from claim benefits paid to us under our business interruption policy related to product contamination losses and a recovery from a vendor’s policy related to an equipment malfunction.

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2024
Income Taxes [Abstract]
INCOME TAXES	16. INCOME TAXES Our income tax expense aggregated $1,340 and $229 (amounting to less than 1% of our loss before income taxes) during the three-month periods ended September 30, 2024 and 2023, respectively, and $4,020 and $3,279 (amounting to less than 1% of our loss before income taxes) during the nine-month periods ended September 30, 2024 and 2023, respectively. As of December 31, 2023, we had federal net operating loss carryforwards of $17,759,519 of which $16,047,612 do not expire and of which $1,711,907 expire in 2034 through 2037 (if not utilized before then) and state net operating loss carryforwards of $4,681,644 that expire in 2037 through 2038 (if not utilized before then). Additionally, we had federal general business tax credit carryforwards of $726,474 that expire in 2028 through 2044 (if not utilized before then) and state tax credit carryforwards of $981,604 that expire in 2024 through 2042 (if not utilized before then). The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the estimated future tax effects of temporary differences between book and tax treatment of assets and liabilities and carryforwards to the extent they are realizable. During the second quarter of 2018, we assessed our historical and near-term future profitability and recorded $563,252 in non-cash income tax expense to create a full valuation allowance against our net deferred tax assets (which consist largely of net operating loss carryforwards and federal and state credits) based on applicable accounting standards and practices. At that time, we had incurred a net loss for six consecutive quarters, had not been profitable on a year-to-date basis since the nine-month period ended September 30, 2017 and projected additional net losses for some period going forward before returning to profitability. Should future profitability be realized at an adequate level, we would be able to release this valuation allowance (resulting in a non-cash income tax benefit) and realize these deferred tax assets before they expire. We will continue to assess the need for the valuation allowance at each quarter and, in the event that actual results differ from these estimates, or we adjust these estimates in future periods, we may need to adjust our valuation allowance. Currently, we adjust the valuation allowance at the end of each quarter to reduce the value of our deferred tax assets to zero. Net operating loss carryforwards, credits, and other tax attributes are subject to review and possible adjustment by the Internal Revenue Service. Section 382 of the Internal Revenue Code contains provisions that could place annual limitations on the future utilization of net operating loss carryforwards and credits in the event of a change in ownership of the Company, as defined. We file income tax returns in the U.S. federal jurisdiction and several state jurisdictions. We currently have no tax examinations in progress. We also have not paid additional taxes, interest or penalties as a result of tax examinations nor do we have any unrecognized tax benefits for any of the periods in the accompanying unaudited financial statements.

Segment Information

Segment Information	9 Months Ended
Segment Information	Sep. 30, 2024
Segment Information [Abstract]
SEGMENT INFORMATION	17. SEGMENT INFORMATION Our business operations (being the development, manufacture and sale of products that improve the health and productivity of dairy and beef cattle) are described in Note 1. Pursuant to Codification Topic 280, Segment Reporting First Defense ® CMT Re-Tain ® Re-Tain ® First Defense ® Re-Tain ® During the Three-Month Scours Mastitis Other Total Product sales $ 5,951,344 $ 60,229 $ — $ 6,011,573 Costs of goods sold 4,364,950 63,069 — 4,428,019 Gross margin 1,586,394 (2,840 ) — 1,583,554 Product development expense 59,140 690,052 36,944 786,136 Sales and marketing expenses 699,584 144,461 — 844,045 Administrative expenses — — 528,267 528,267 Operating expenses 758,724 834,513 565,211 2,158,448 NET OPERATING INCOME (LOSS) $ 827,670 $ (837,353 ) $ (565,211 ) $ (574,894 ) During the Three-Month Scours Mastitis Other Total Product sales $ 5,360,063 $ 36,437 $ — $ 5,396,500 Costs of goods sold 4,095,164 34,455 — 4,129,619 Gross margin 1,264,899 1,982 — 1,266,881 Product development expenses — 1,082,346 36,143 1,118,489 Sales and marketing expenses 641,682 175,804 — 817,486 Administrative expenses — — 514,952 514,952 Operating expenses 641,682 1,258,150 551,095 2,450,927 NET OPERATING INCOME (LOSS) $ 623,217 $ (1,256,168 ) $ (551,095 ) $ (1,184,046 ) Scours Mastitis Other Total Total Assets as of September 30, 2024 $ 23,672,583 $ 16,798,955 $ 3,977,335 $ 44,448,873 Total Assets as of September 30, 2023 $ 24,119,683 $ 18,132,922 $ 2,292,417 $ 44,545,022 Depreciation and amortization expense during the three-month period ended September 30, 2024 $ 346,430 $ 319,815 $ 19,682 $ 685,927 Depreciation and amortization expense during the three-month period ended September 30, 2023 $ 355,673 $ 328,381 $ 25,044 $ 709,098 Capital Expenditures during the three-month period ended September 30, 2024 $ 87,286 $ 1,126 $ — $ 88,412 Capital Expenditures during the three-month period ended September 30, 2023 $ 341,386 $ 79,129 $ — $ 420,515 During the Nine-Month Scours Mastitis Other Total Product sales $ 18,602,054 $ 139,986 $ — $ 18,742,040 Costs of goods sold 13,487,348 145,294 — 13,632,642 Gross margin 5,114,706 (5,308 ) — 5,109,398 Product development expense 154,233 2,821,525 103,431 3,079,189 Sales and marketing expenses 2,224,836 405,089 — 2,629,925 Administrative expenses — — 1,661,838 1,661,838 Operating expenses 2,379,069 3,226,614 1,765,269 7,370,952 NET OPERATING INCOME (LOSS) $ 2,735,637 $ (3,231,922 ) $ (1,765,269 ) $ (2,261,554 ) During the Nine-Month Scours Mastitis Other Total Product sales $ 12,253,555 $ 122,153 $ — $ 12,375,708 Costs of goods sold 9,652,292 111,872 — 9,764,164 Gross margin 2,601,263 10,281 — 2,611,544 Product development expenses 2,543 3,220,075 105,779 3,328,397 Sales and marketing expenses 1,890,404 526,297 — 2,416,701 Administrative expenses — — 1,611,026 1,611,026 Operating expenses 1,892,947 3,746,372 1,716,805 7,356,124 NET OPERATING INCOME (LOSS) $ 708,316 $ (3,736,091 ) $ (1,716,805 ) $ (4,744,580 ) Scours Mastitis Other Total Total Assets as of September 30, 2024 $ 23,672,583 $ 16,798,955 $ 3,977,335 $ 44,448,873 Total Assets as of September 30, 2023 $ 24,119,683 $ 18,132,922 $ 2,292,417 $ 44,545,022 Depreciation and amortization expense during the nine-month period ended September 30, 2024 $ 1,027,711 $ 958,260 $ 59,221 $ 2,045,192 Depreciation and amortization expense during the nine-month period ended September 30, 2023 $ 1,020,909 $ 969,666 $ 64,066 $ 2,054,641 Capital Expenditures during the nine-month period ended September 30, 2024 $ 235,600 $ 33,909 $ — $ 269,509 Capital Expenditures during the nine-month period ended September 30, 2023 $ 1,038,033 $ 773,136 $ — $ 1,811,169 During the Year Ended December 31, 2023 Scours Mastitis Other Total Product sales $ 17,293,933 $ 177,736 $ — $ 17,471,669 Costs of goods sold 13,453,514 148,871 — 13,602,385 Gross margin 3,840,419 28,865 — 3,869,284 Product development expense 11,103 4,242,329 141,420 4,394,852 Sales and marketing expenses 2,447,137 641,078 — 3,088,215 Administrative expenses — — 2,134,295 2,134,295 Operating expenses 2,458,240 4,883,407 2,275,715 9,617,362 NET OPERATING INCOME (LOSS) $ 1,382,179 $ (4,854,542 ) $ (2,275,715 ) $ (5,748,078 ) During the Year Ended December 31, 2022 Scours Mastitis Other Total Product sales $ 18,411,949 $ 154,558 $ 1,455 $ 18,567,962 Costs of goods sold 10,754,189 136,347 28,647 10,919,183 Gross margin 7,657,760 18,211 (27,192 ) 7,648,779 Product development expenses 66,346 4,317,921 109,605 4,493,872 Sales and marketing expenses 1,871,926 1,318,107 — 3,190,033 Administrative expenses — — 2,263,817 2,263,817 Operating expenses 1,938,272 5,636,028 2,373,422 9,947,722 NET OPERATING INCOME (LOSS) $ 5,719,488 $ (5,617,817 ) $ (2,400,614 ) $ (2,298,943 ) Scours Mastitis Other Total Total Assets as of December 31, 2023 $ 24,735,413 $ 17,827,839 $ 1,244,850 $ 43,808,102 Total Assets as of December 31, 2022 $ 20,539,523 $ 18,315,492 $ 6,005,634 $ 44,860,649 Depreciation and amortization expense during the year ended December 31, 2023 $ 1,365,988 $ 1,287,600 $ 86,032 $ 2,739,620 Depreciation and amortization expense during the year ended December 31, 2022 $ 1,169,011 $ 1,263,318 $ 62,912 $ 2,495,241 Capital Expenditures during the year ended December 31, 2023 $ 1,096,819 $ 795,694 $ — $ 1,892,513 Capital Expenditures during the year ended December 31, 2022 $ 3,497,834 $ 429,988 $ 47,452 $ 3,975,274

Related Party Transactions

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	18. RELATED PARTY TRANSACTIONS David S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc., a domestic distributor of our products (the First Defense Ò product line and CMT

Employee Benefits

Employee Benefits	9 Months Ended
Employee Benefits	Sep. 30, 2024
Employee Benefits [Abstract]
EMPLOYEE BENEFITS	19. EMPLOYEE BENEFITS We have a 401(k) savings plan (the Plan) in which all employees completing one month of service with the Company are eligible to participate. Participants may contribute up to the maximum amount allowed by the Internal Revenue Service. We currently match 100% of the first 3% of each employee’s salary that is contributed to the Plan and 50% of the next 2% of each employee’s salary that is contributed to the Plan. Under this matching plan, we paid $55,989 and $50,126 into the Plan for the three-month periods ended September 30, 2024 and 2023, respectively, and $159,504 and $135,698 for the nine-month periods ended September 30, 2024 and 2023, respectively.

Subsequent Events

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	20. SUBSEQUENT EVENTS We have evaluated subsequent events through the time of filing on the date we have issued this Quarterly Report on Form 10-Q. Subsequent to September 30, 2024 and through October 30, 2024, we sold an additional 78,492 shares raising an additional $289,719 in gross proceeds pursuant to the at the market offering conducted pursuant to the ATM Agreement. See Note 13. As of the time of filing, there were no other material, reportable subsequent events.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (701,690)	$ (940,000)	$ (2,671,184)	$ (4,634,767)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
Accounting Policies, by Policy (Policies)	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	(a) Basis of Presentation We have prepared the accompanying unaudited financial statements reflecting all adjustments (which are of a normal recurring nature) that are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets Generally Accepted Accounting Principles (GAAP) that we follow to ensure we accurately report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB Accounting Standards Codification
Cash and Cash Equivalents	(b) Cash and Cash Equivalents We consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities backed by the U.S. government. We hold no cash or cash equivalents in excess of Federal Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor. See Note 3.
Trade Accounts Receivable	(c) Trade Accounts Receivable Accounts receivable are carried at the original invoice amount less an estimate made for doubtful collection when applicable. Management determines the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts and other relevant factors. Accounts receivable are considered to be past due if a portion of the receivable balance is outstanding for more than 30 days. Past due accounts receivable are subject to an interest charge. It was not necessary to charge interest on past due accounts during the nine-month periods ended September 30, 2024 or 2023 because the time past due was not significant, and there was no accrual for such interest charges as of September 30, 2024 or December 31, 2023. Accounts receivable are written off when deemed uncollectible. No accounts receivable were written off during the nine-month periods ended September 30, 2024 or 2023. Recoveries of accounts receivable previously written off are recorded as income when received. No such recoveries were recorded during the nine-month periods ended September 30, 2024 or 2023. As of September 30, 2024 and December 31, 2023, we determined that no allowance for doubtful accounts was necessary. See Note 4.
Inventory	(d) Inventory Inventory includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or net realizable value (determined as the estimated selling price in the normal course of business, less reasonably predictable costs of completion, disposal and transportation). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. At each balance sheet date, we evaluate our ending inventories for excess quantities and obsolescence. Inventories that we consider excess or obsolete are written down to estimated net realizable value. Once inventory is written down and a new cost basis is established, it is not written back up. We believe that supplies and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products when feasible. See Note 5.
Property, Plant and Equipment, net	(e) Property, Plant and Equipment, net We depreciate property, plant and equipment on the straight-line method by charges to operations and costs of goods sold in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. The facility we have constructed at 33 Caddie Lane to produce the Nisin Drug Substance (DS) for Re-Tain ® Building 33 First Defense ® Building 175A Building 175B
Operating Leases	(f) Operating Leases We account for our real estate leases using a right-of-use model, which recognizes that at the date of commencement, a lessee has a financial obligation to make lease payments to the lessor for the right to use the underlying asset during the lease term and recognizes a corresponding right-of-use (ROU) asset related to this right. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the expected lease term. The ROU asset is also adjusted for any lease prepayments made, lease incentives received and initial direct costs incurred. For operating leases with lease payments that fluctuate over the lease term, the total lease costs are recognized on a straight-line basis over the lease term. Our leases, at times, may include options to extend the term of the lease. When it is reasonably certain that we will exercise the option, we include the impact of the option in the lease term for purposes of determining future lease payments. For all underlying classes of assets, we made an accounting policy election to not recognize assets or liabilities for leases with a term of twelve months or less and to account for all components in a lease arrangement as a single combined lease component. Short-term lease payments are recognized on a straight-line basis. Certain of our lease agreements include variable rent payments, consisting primarily of amounts paid to the lessor based on cost or consumption, such as maintenance and real estate taxes. These costs are recognized in the period in which the obligation is incurred. Because our leases do not specify an implicit rate, we use an incremental borrowing rate based on information available at the lease commencement date to determine the present value of the lease payments. We evaluate our ROU asset for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. See Notes 2(h) and 12 for additional information.
Intangible Assets and Goodwill	(g) Intangible Assets and Goodwill We amortize intangible assets on the straight-line method by charges to costs of goods sold in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. We have recorded intangible assets related to customer relationships, non-compete agreements and developed technology, each with defined useful lives. Amounts paid in excess of the fair value of the net assets (including tax attributes) are recorded as goodwill under the acquisition method of accounting. We assess the impairment of intangible assets that have indefinite lives (when applicable) and goodwill (at the reporting unit level) on an annual basis (as of December 31 st No
Valuation of Long-Lived Assets	(h) Valuation of Long-Lived Assets We periodically evaluate our long-lived assets, consisting principally of property, plant and equipment, operating lease right-of-use asset and amortizable intangible assets, for potential impairment. In accordance with the applicable accounting guidance for the treatment of long-lived assets, we review the carrying value of our long-lived assets or asset group that is held and used, including intangible assets subject to amortization, for impairment whenever events and circumstances indicate that the carrying value of the assets may not be recoverable. Under the held for use approach, the asset or asset group to be tested for impairment should represent the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. No
Fair Value Measurements	(i) Fair Value Measurements In determining fair value measurements, we follow the provisions of Codification Topic 820, Fair Value Measurements and Disclosures Level 1 — Pricing inputs are quoted prices available in active markets for identical assets or liabilities as of the measurement date. Level 2 — Pricing inputs are quoted prices for similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 3 — Pricing inputs are unobservable for the assets or liabilities, that is, inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level of an asset or liability within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. We also hold money market accounts in our bank account, which are classified as cash equivalents and measured at fair value. The fair value of these investments is based on their closing published net asset value. We assess the levels of the investments at each measurement date, and transfers between levels are recognized on the actual date of the event or change in circumstances that caused the transfer in accordance with our accounting policy regarding the recognition of transfers between levels of the fair value hierarchy. During the nine-month periods ended September 30, 2024 and 2023, there were no transfers between levels. As of September 30, 2024 and December 31, 2023, our Level 1 assets measured at fair value by quoted prices in active markets consisted of cash and money market accounts. There were no assets or liabilities measured at fair value on a nonrecurring basis as of September 30, 2024 or December 31, 2023. The carrying values of our cash and money market accounts as of September 30, 2024 and December 31, 2023 approximated their fair market values. Due to inflation and the changing interest rate environment, the carrying values of our fixed rate bank debt as of September 30, 2024 and December 31, 2023 differed from their fair market values. These values are reflected in the following tables: As of September 30, 2024 Level 1 Level 2 Level 3 Total Assets: Cash and money market accounts $ 3,808,633 $ — $ — $ 3,808,633 Liabilities: Bank debt $ — $ 9,703,821 $ — $ 9,703,821 As of December 31, 2023 Level 1 Level 2 Level 3 Total Assets: Cash and money market accounts $ 978,741 $ — $ — $ 978,741 Liabilities: Bank debt $ — $ 10,431,817 $ — $ 10,431,817
Concentration of Risk	(j) Concentration of Risk Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table: During the Three-Month During the Nine-Month 2024 2023 2024 2023 Company A 43 % 50 % 44 % 48 % Company B 31 % 29 % 33 % 31 % Trade accounts receivable due from significant customers that amounted to 10% or more of our total trade accounts receivable are detailed in the following table: As of As of Company A 37 % 43 % Company B 34 % 36 %
Revenue Recognition	(k) Revenue Recognition We recognize revenue in accordance with Codification Topic 606, Revenue from Contracts with Customers (ASC 606)
Expense Recognition	(l) Expense Recognition We do not incur costs in connection with product sales to customers that are eligible for capitalization. Advertising costs are expensed when incurred, which is generally during the month in which the advertisement is published. All product development expenses are expensed as incurred, as are all related patent costs. We capitalize costs to produce inventory during the production cycle, and these costs are charged to costs of goods sold when the inventory is sold to a customer or is deemed to be in excess or obsolete.
Income Taxes	(m) Income Taxes We account for income taxes in accordance with Codification Topic 740, Income Taxes Codification Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. With few exceptions, we are no longer subject to income tax examinations by tax authorities for years before 2021. We have evaluated the positions taken on our filed tax returns and have concluded that no uncertain tax positions existed as of September 30, 2024 or December 31, 2023. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 16.
Stock-Based Compensation	(n) Stock-Based Compensation We account for stock-based compensation in accordance with Codification Topic 718, Compensation-Stock Compensation
Net Loss Per Common Share	(o) Net Loss Per Common Share Net loss per common share has been computed in accordance with Codification Topic 260-10, Earnings Per Share During the Three-Month During the Nine-Month 2024 2023 2024 2023 Net loss attributable to stockholders $ (701,690 ) $ (940,000 ) $ (2,671,184 ) $ (4,634,767 ) Weighted average common shares outstanding - Basic 8,164,423 7,746,864 7,908,425 7,746,864 Dilutive impact of share-based compensation awards — — — — Weighted average common shares outstanding - Diluted 8,164,423 7,746,864 7,908,425 7,746,864 Net loss per share: Basic $ (0.09 ) $ (0.12 ) $ (0.34 ) $ (0.60 ) Diluted $ (0.09 ) $ (0.12 ) $ (0.34 ) $ (0.60 )
Use of Estimates	(p) Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ from those estimates and are subject to change in the near term. Changes in estimates are recorded during the period in which they become known. Significant estimates include our valuation of inventory, deferred tax assets and costs of goods sold
New Accounting Pronouncements Not Yet Adopted	(q) New Accounting Pronouncements Not Yet Adopted In November of 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, In December of 2023, the FASB issued ASU 2023-09 , Income Taxes (Topic 740): Improvements to Income Tax Disclosures

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
Summary of Significant Accounting Policies (Tables)	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis	These values are reflected in the following tables: As of September 30, 2024 Level 1 Level 2 Level 3 Total Assets: Cash and money market accounts $ 3,808,633 $ — $ — $ 3,808,633 Liabilities: Bank debt $ — $ 9,703,821 $ — $ 9,703,821 As of December 31, 2023 Level 1 Level 2 Level 3 Total Assets: Cash and money market accounts $ 978,741 $ — $ — $ 978,741 Liabilities: Bank debt $ — $ 10,431,817 $ — $ 10,431,817
Schedule of Concentration of Risk	Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table: During the Three-Month During the Nine-Month 2024 2023 2024 2023 Company A 43 % 50 % 44 % 48 % Company B 31 % 29 % 33 % 31 % As of As of Company A 37 % 43 % Company B 34 % 36 %
Schedule of Net Income (Loss) Per Common Share	Outstanding stock options that were not included in this calculation because the effect would be anti-dilutive amounted to 661,000 and 616,500 during the three-month periods ended September 30, 2024 and 2023, respectively, and 661,000 and 616,500 during the nine-month periods ended September 30, 2024 and 2023, respectively. During the Three-Month During the Nine-Month 2024 2023 2024 2023 Net loss attributable to stockholders $ (701,690 ) $ (940,000 ) $ (2,671,184 ) $ (4,634,767 ) Weighted average common shares outstanding - Basic 8,164,423 7,746,864 7,908,425 7,746,864 Dilutive impact of share-based compensation awards — — — — Weighted average common shares outstanding - Diluted 8,164,423 7,746,864 7,908,425 7,746,864 Net loss per share: Basic $ (0.09 ) $ (0.12 ) $ (0.34 ) $ (0.60 ) Diluted $ (0.09 ) $ (0.12 ) $ (0.34 ) $ (0.60 )

Inventory (Tables)

Inventory (Tables)	9 Months Ended
Inventory (Tables)	Sep. 30, 2024
Inventory [Abstract]
Schedule of Inventory	Inventory consisted of the following: As of As of Raw materials $ 1,313,766 $ 1,594,028 Work-in-process 6,124,394 5,815,194 Finished goods 22,292 402,619 Total $ 7,460,452 $ 7,811,841

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
Prepaid Expenses and Other Current Assets (Tables)	Sep. 30, 2024
Prepaid Expenses and Other Current Assets [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following: As of As of Prepaid expenses $ 277,146 $ 454,152 Other receivables 33,342 39,733 Total $ 310,488 $ 493,885

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	9 Months Ended
Property, Plant and Equipment, Net (Tables)	Sep. 30, 2024
Property, Plant and Equipment, Net [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consisted of the following: Estimated Useful Lives As of As of Laboratory and manufacturing equipment 3-10 $ 21,183,888 $ 20,953,601 Buildings and improvements 10-39 20,858,708 20,784,565 Office furniture and equipment 3-10 1,053,436 1,036,374 Construction in progress n/a 2,588,630 2,768,224 Land n/a 516,867 516,867 Property, plant and equipment, gross 46,201,529 46,059,631 Accumulated depreciation (20,381,196 ) (18,483,948 ) Property, plant and equipment, net $ 25,820,333 $ 27,575,683

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
Intangible Assets (Tables)	Sep. 30, 2024
Intangible Assets [Abstract]
Schedule of Intangible Assets	Intangible assets as of September 30, 2024 consisted of the following: Gross Carrying Accumulated Net Book Developed technology $ 184,100 $ (161,087 ) $ 23,013 Customer relationships 1,300 (1,138 ) 162 Non-compete agreements 5,640 (4,935 ) 705 Total $ 191,040 $ (167,160 ) $ 23,880 Gross Carrying Accumulated Net Book Developed technology $ 184,100 $ (147,280 ) $ 36,820 Customer relationships 1,300 (1,040 ) 260 Non-compete agreements 5,640 (4,512 ) 1,128 Total $ 191,040 $ (152,832 ) $ 38,208

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
Accounts Payable and Accrued Expenses (Tables)	Sep. 30, 2024
Accounts Payable and Accrued Expenses [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following: As of As of Accounts payable – trade $ 876,836 $ 874,558 Accounts payable – capital 6,378 13,175 Accrued payroll 1,142,318 942,999 Accrued professional fees 101,725 97,800 Accrued other 376,112 192,754 Income tax payable 1,166 3,051 Total $ 2,504,535 $ 2,124,337

Bank Debt (Tables)

Bank Debt (Tables)	9 Months Ended
Bank Debt (Tables)	Sep. 30, 2024
Bank Debt [Abstract]
Schedule of Debt Proceeds Received and Principal Repayments	Debt proceeds received and principal repayments made (excluding our $1,000,000 line of credit) are reflected by loan during the periods as described in the tables below: During the Three-Month Period Ended September 30, 2024 During the Three-Month Proceeds from Debt Principal Proceeds from Debt Principal Loan #1 $ — $ 57,671 $ — $ 55,619 Loan #2 — 128,534 — 124,020 Loan #3 — 24,173 — 23,002 Loan #4 — 53,505 — 51,622 Loan #5 — 16,719 — 15,909 Loan #6 — 59,191 2,000,000 36,582 Loan #7 — 28,456 1,000,000 18,983 Total $ — $ 368,249 $ 3,000,000 $ 325,737 During the Nine-Month Period Ended September 30, 2024 During the Nine-Month Period Ended September 30, 2023 Proceeds from Debt Principal Proceeds from Debt Principal Loan #1 $ — $ 172,017 $ — $ 166,527 Loan #2 — 382,324 — 369,154 Loan #3 — 71,629 — 68,156 Loan #4 — 159,171 — 153,704 Loan #5 — 49,542 — 15,909 Loan #6 — 174,804 2,000,000 36,582 Loan #7 — 84,619 1,000,000 18,983 Total $ — $ 1,094,106 $ 3,000,000 $ 829,015 During the Year During the Year Proceeds from Debt Principal Proceeds from Debt Principal Loan #1 $ — $ 223,222 $ 2,000,000 $ 199,013 Loan #2 — 494,455 — 477,237 Loan #3 — 91,446 — 22,160 Loan #4 — 205,884 — 198,715 Loan #5 — 32,017 — — Loan #6 2,000,000 93,054 — — Loan #7 1,000,000 45,696 — — Total $ 3,000,000 $ 1,185,774 $ 2,000,000 $ 897,125
Schedule of Principal Payments Bank Loans Outstanding	Principal payments (net of debt issuance and debt discount costs) due under bank loans outstanding as of September 30, 2024 (excluding our $1,000,000 line of credit) are reflected in the following table by the year that payments are due: During the During the Years Ending December 31, 2024 2025 2026 2027 2028 Thereafter Total Loan #1 $ 58,765 $ 239,876 $ 248,604 $ 257,649 $ 266,537 $ 4,598,457 $ 5,669,888 Loan #2 129,801 530,738 549,881 140,436 — — 1,350,856 Loan #3 24,476 101,000 106,146 83,143 — — 314,765 Loan #4 54,055 220,994 228,965 240,442 — — 744,456 Loan #5 16,929 69,856 73,415 77,156 81,086 — 318,442 Loan #6 60,581 253,003 1,418,558 — — — 1,732,142 Loan #7 29,617 124,364 715,704 — — — 869,685 Subtotal 374,224 1,539,831 3,341,273 798,826 347,623 4,598,457 11,000,234 Debt issuance cost (5,583 ) (21,314 ) (13,580 ) (5,420 ) (3,513 ) (11,347 ) (60,757 ) Debt discount cost (5,223 ) (20,891 ) (11,344 ) — — — (37,458 ) Total $ 363,418 $ 1,497,626 $ 3,316,349 $ 793,406 $ 344,110 $ 4,587,110 $ 10,902,019

Operating Lease (Tables)

Operating Lease (Tables)	9 Months Ended
Operating Lease (Tables)	Sep. 30, 2024
Operating Lease [Abstract]
Schedule of Lease Costs and Other Lease Information	Variable lease cost primarily represents variable payments such as real estate taxes and common area maintenance. The following tables describe our lease costs and other lease information: During the Three-Month During the Nine-Month 2024 2023 2024 2023 Lease Cost Operating lease cost $ 106,880 $ 98,714 $ 320,639 $ 244,954 Variable lease cost 21,486 9,720 50,638 27,054 Total lease cost $ 128,366 $ 108,434 $ 371,277 $ 272,008 Operating Lease Cash paid for operating lease liabilities $ 144,315 $ 69,742 $ 432,945 $ 131,476 Weighted average remaining lease term (in years) 18.3 19.3 18.3 19.3 Weighted average discount rate 6.6 % 6.3 % 6.6 % 6.3 %
Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases	Future lease payments required under non-cancelable operating leases in effect as of September 30, 2024 were as follows: Amount During the three-month period ending December 31, 2024 $ 144,315 During the years ending December 31, 2025 711,623 2026 349,744 2027 356,732 2028 363,870 Thereafter 5,949,488 Total lease payments (undiscounted cash flows) 7,875,772 Less: imputed interest (discount effect of cash flows) (3,245,124 ) Total operating liabilities $ 4,630,648

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	9 Months Ended
Stockholders’ Equity (Tables)	Sep. 30, 2024
Stockholders’ Equity [Abstract]
Schedule of Activity Under the Stock Option Plans	Activity under the stock option plans described above was as follows: 2010 Plan 2017 Plan Weighted Average Exercise Price Aggregate Intrinsic Value (1) Outstanding as of December 31, 2022 202,500 402,500 $ 7.19 $ (661,310 ) Grants — 122,000 $ 5.16 Terminations/forfeitures (2) (10,000 ) (94,500 ) $ 7.12 Exercises (4,000 ) — $ 4.69 Outstanding as of December 31, 2023 188,500 430,000 $ 6.82 $ (1,071,121 ) Grants — 73,000 $ 3.80 Terminations/forfeitures (2) (5,000 ) (25,500 ) $ 6.75 Exercises — — $ — Outstanding as of September 30, 2024 183,500 477,500 $ 6.49 $ (1,891,421 ) Vested as of September 30, 2024 183,500 136,500 $ 6.97 $ (1,068,740 ) Vested and expected to vest as of September 30, 2024 183,500 477,500 $ 6.49 $ (1,891,421 ) Reserved for future grants — 154,500 (1) Intrinsic value is the difference between the fair market value of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise price). (2) Terminations and forfeitures are recognized when they occur.
Schedule of Additional Information About the Stock Option Plans	The following table displays additional information about the stock option plans described above: Number of Shares Weighted Average Weighted Average Exercise Price Non-vested stock options as of December 31, 2023 337,500 $ 3.66 $ 7.14 Non-vested stock options as of September 30, 2024 341,000 $ 3.14 $ 6.04 Stock options granted during the nine-month period ended September 30, 2024 73,000 $ 1.72 $ 3.80 Stock options that vested during the nine-month period ended September 30, 2024 54,000 $ 4.31 $ 9.73 Stock options that were terminated or forfeited during the nine-month period ended September 30, 2024 30,500 $ 3.36 $ 6.75
Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions	The fair value of each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the following weighted-average assumptions: During the Three-Month During the Nine-Month 2024 2023 2024 2023 Risk-free interest rate (1) 3.48 % n/a (4) 3.70 % 3.48 % Dividend yield (2) 0 % 0 % 0 % 0 % Expected volatility (2) 52 % n/a (4) 51 % 54 % Expected life (3) 4.1 years n/a (4) 4.3 years 6.2 years (1) The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected option term. (2) The dividend yield and expected volatility are derived from averages of our historical data. (3) The expected life is calculated utilizing the simplified method, which uses the mid-point between the vesting period and the contractual term as the expected life. (4) These values are not applicable because no

Revenue (Tables)

Revenue (Tables)	9 Months Ended
Revenue (Tables)	Sep. 30, 2024
Revenue [Abstract]
Schedule of Product Sales Disaggregated by Geographic Area	The following table presents our product sales disaggregated by geographic area: During the Three-Month During the Nine-Month 2024 % 2023 % 2024 % 2023 % United States $ 5,216,401 87 % $ 4,923,265 91 % $ 16,449,178 88 % $ 11,173,686 90 % Other 795,172 13 % 473,235 9 % 2,292,862 12 % 1,202,022 10 % Total Product Sales $ 6,011,573 100 % $ 5,396,500 100 % $ 18,742,040 100 % $ 12,375,708 100 %
Schedule of Product Sales Disaggregated by Major Product Category	The following table presents our product sales disaggregated by major product category: During the Three-Month During the Nine-Month 2024 % 2023 % 2024 % 2023 % First Defense ® product line $ 5,951,344 99 % $ 5,360,063 99 % $ 18,602,053 99 % $ 12,253,555 99 % Other animal health 60,229 1 % 36,437 1 % 139,987 1 % 122,153 1 % Total Product Sales $ 6,011,573 100 % $ 5,396,500 100 % $ 18,742,040 100 % $ 12,375,708 100 %

Other Expenses, Net (Tables)

Other Expenses, Net (Tables)	9 Months Ended
Other Expenses, Net (Tables)	Sep. 30, 2024
Other Expenses, Net [Abstract]
Schedule of Other Expenses Net	Other expenses net, consisted of the following: During the Three-Month During the Nine-Month 2024 2023 2024 2023 Interest expense (1) $ 144,141 $ 144,616 $ 432,529 $ 323,177 Loss (gain) on disposal of property, plant and equipment — (68 ) 14,557 8,099 Interest income (18,685 ) (23,696 ) (41,476 ) (79,134 ) Insurance recoveries (2) — (365,127 ) — (365,127 ) Income - other — — — (107 ) Other expenses (income), net $ 125,456 $ (244,275 ) $ 405,610 $ (113,092 ) (1) Interest expense includes amortization of debt issuance and debt discount costs of $10,805 and $8,687 during the three-month periods ended September 30, 2024 or 2023, respectively, and $31,859 and $12,525 during the nine-month periods ended September 30, 2024 and 2023, respectively. (2) The income from insurance recoveries resulted from claim benefits paid to us under our business interruption policy related to product contamination losses and a recovery from a vendor’s policy related to an equipment malfunction.

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
Segment Information (Tables)	Sep. 30, 2024
Segment Information [Abstract]
Schedule of Segment Information	During the Three-Month Scours Mastitis Other Total Product sales $ 5,951,344 $ 60,229 $ — $ 6,011,573 Costs of goods sold 4,364,950 63,069 — 4,428,019 Gross margin 1,586,394 (2,840 ) — 1,583,554 Product development expense 59,140 690,052 36,944 786,136 Sales and marketing expenses 699,584 144,461 — 844,045 Administrative expenses — — 528,267 528,267 Operating expenses 758,724 834,513 565,211 2,158,448 NET OPERATING INCOME (LOSS) $ 827,670 $ (837,353 ) $ (565,211 ) $ (574,894 ) During the Three-Month Scours Mastitis Other Total Product sales $ 5,360,063 $ 36,437 $ — $ 5,396,500 Costs of goods sold 4,095,164 34,455 — 4,129,619 Gross margin 1,264,899 1,982 — 1,266,881 Product development expenses — 1,082,346 36,143 1,118,489 Sales and marketing expenses 641,682 175,804 — 817,486 Administrative expenses — — 514,952 514,952 Operating expenses 641,682 1,258,150 551,095 2,450,927 NET OPERATING INCOME (LOSS) $ 623,217 $ (1,256,168 ) $ (551,095 ) $ (1,184,046 ) Scours Mastitis Other Total Total Assets as of September 30, 2024 $ 23,672,583 $ 16,798,955 $ 3,977,335 $ 44,448,873 Total Assets as of September 30, 2023 $ 24,119,683 $ 18,132,922 $ 2,292,417 $ 44,545,022 Depreciation and amortization expense during the three-month period ended September 30, 2024 $ 346,430 $ 319,815 $ 19,682 $ 685,927 Depreciation and amortization expense during the three-month period ended September 30, 2023 $ 355,673 $ 328,381 $ 25,044 $ 709,098 Capital Expenditures during the three-month period ended September 30, 2024 $ 87,286 $ 1,126 $ — $ 88,412 Capital Expenditures during the three-month period ended September 30, 2023 $ 341,386 $ 79,129 $ — $ 420,515 During the Nine-Month Scours Mastitis Other Total Product sales $ 18,602,054 $ 139,986 $ — $ 18,742,040 Costs of goods sold 13,487,348 145,294 — 13,632,642 Gross margin 5,114,706 (5,308 ) — 5,109,398 Product development expense 154,233 2,821,525 103,431 3,079,189 Sales and marketing expenses 2,224,836 405,089 — 2,629,925 Administrative expenses — — 1,661,838 1,661,838 Operating expenses 2,379,069 3,226,614 1,765,269 7,370,952 NET OPERATING INCOME (LOSS) $ 2,735,637 $ (3,231,922 ) $ (1,765,269 ) $ (2,261,554 ) During the Nine-Month Scours Mastitis Other Total Product sales $ 12,253,555 $ 122,153 $ — $ 12,375,708 Costs of goods sold 9,652,292 111,872 — 9,764,164 Gross margin 2,601,263 10,281 — 2,611,544 Product development expenses 2,543 3,220,075 105,779 3,328,397 Sales and marketing expenses 1,890,404 526,297 — 2,416,701 Administrative expenses — — 1,611,026 1,611,026 Operating expenses 1,892,947 3,746,372 1,716,805 7,356,124 NET OPERATING INCOME (LOSS) $ 708,316 $ (3,736,091 ) $ (1,716,805 ) $ (4,744,580 ) Scours Mastitis Other Total Total Assets as of September 30, 2024 $ 23,672,583 $ 16,798,955 $ 3,977,335 $ 44,448,873 Total Assets as of September 30, 2023 $ 24,119,683 $ 18,132,922 $ 2,292,417 $ 44,545,022 Depreciation and amortization expense during the nine-month period ended September 30, 2024 $ 1,027,711 $ 958,260 $ 59,221 $ 2,045,192 Depreciation and amortization expense during the nine-month period ended September 30, 2023 $ 1,020,909 $ 969,666 $ 64,066 $ 2,054,641 Capital Expenditures during the nine-month period ended September 30, 2024 $ 235,600 $ 33,909 $ — $ 269,509 Capital Expenditures during the nine-month period ended September 30, 2023 $ 1,038,033 $ 773,136 $ — $ 1,811,169 During the Year Ended December 31, 2023 Scours Mastitis Other Total Product sales $ 17,293,933 $ 177,736 $ — $ 17,471,669 Costs of goods sold 13,453,514 148,871 — 13,602,385 Gross margin 3,840,419 28,865 — 3,869,284 Product development expense 11,103 4,242,329 141,420 4,394,852 Sales and marketing expenses 2,447,137 641,078 — 3,088,215 Administrative expenses — — 2,134,295 2,134,295 Operating expenses 2,458,240 4,883,407 2,275,715 9,617,362 NET OPERATING INCOME (LOSS) $ 1,382,179 $ (4,854,542 ) $ (2,275,715 ) $ (5,748,078 ) During the Year Ended December 31, 2022 Scours Mastitis Other Total Product sales $ 18,411,949 $ 154,558 $ 1,455 $ 18,567,962 Costs of goods sold 10,754,189 136,347 28,647 10,919,183 Gross margin 7,657,760 18,211 (27,192 ) 7,648,779 Product development expenses 66,346 4,317,921 109,605 4,493,872 Sales and marketing expenses 1,871,926 1,318,107 — 3,190,033 Administrative expenses — — 2,263,817 2,263,817 Operating expenses 1,938,272 5,636,028 2,373,422 9,947,722 NET OPERATING INCOME (LOSS) $ 5,719,488 $ (5,617,817 ) $ (2,400,614 ) $ (2,298,943 ) Scours Mastitis Other Total Total Assets as of December 31, 2023 $ 24,735,413 $ 17,827,839 $ 1,244,850 $ 43,808,102 Total Assets as of December 31, 2022 $ 20,539,523 $ 18,315,492 $ 6,005,634 $ 44,860,649 Depreciation and amortization expense during the year ended December 31, 2023 $ 1,365,988 $ 1,287,600 $ 86,032 $ 2,739,620 Depreciation and amortization expense during the year ended December 31, 2022 $ 1,169,011 $ 1,263,318 $ 62,912 $ 2,495,241 Capital Expenditures during the year ended December 31, 2023 $ 1,096,819 $ 795,694 $ — $ 1,892,513 Capital Expenditures during the year ended December 31, 2022 $ 3,497,834 $ 429,988 $ 47,452 $ 3,975,274

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Summary of Significant Accounting Policies [Line Items]
Federal deposit insurance corporation limits	$ 250,000		$ 250,000
Asset depreciated percentage	86%		86%
Goodwill impairments
Impairment of recognized
Stock-based compensation	$ 77,557	$ 96,434	$ 256,688	$ 268,207
Anti-dilutive amounted (in Shares)	661,000	616,500	661,000	616,500
Nisin Drug Substance [Member]
Summary of Significant Accounting Policies [Line Items]
Useful life	10 years		10 years
Leasehold Improvements [Member]
Summary of Significant Accounting Policies [Line Items]
Useful life	10 years		10 years

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis - Fair Value, Nonrecurring [Member] - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Assets:
Cash and money market accounts	$ 3,808,633	$ 978,741
Liabilities:
Bank debt	9,703,821	10,431,817
Level 1 [Member]
Assets:
Cash and money market accounts	3,808,633	978,741
Liabilities:
Bank debt
Level 2 [Member]
Assets:
Cash and money market accounts
Liabilities:
Bank debt	9,703,821	10,431,817
Level 3 [Member]
Assets:
Cash and money market accounts
Liabilities:
Bank debt

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of Concentration of Risk - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023
Company A [Member] \| Product sales [Member]
Schedule of Concentration of Risk [Line Items]
Concentration risk, percentage	43%	50%	44%		48%
Company A [Member] \| Trade accounts receivable [Member]
Schedule of Concentration of Risk [Line Items]
Concentration risk, percentage			37%	43%
Company B [Member] \| Product sales [Member]
Schedule of Concentration of Risk [Line Items]
Concentration risk, percentage	31%	29%	33%		31%
Company B [Member] \| Trade accounts receivable [Member]
Schedule of Concentration of Risk [Line Items]
Concentration risk, percentage			34%	36%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details) - Schedule of Net Income (Loss) Per Common Share - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Schedule of Net Income (Loss) Per Common Share [Abstract]
Net loss attributable to stockholders (in Dollars)	$ (701,690)	$ (940,000)	$ (2,671,184)	$ (4,634,767)
Weighted average common shares outstanding - Basic	8,164,423	7,746,864	7,908,425	7,746,864
Dilutive impact of share-based compensation awards
Weighted average common shares outstanding - Diluted	8,164,423	7,746,864	7,908,425	7,746,864
Net loss per share:
Basic (in Dollars per share)	$ (0.09)	$ (0.12)	$ (0.34)	$ (0.6)
Diluted (in Dollars per share)	$ (0.09)	$ (0.12)	$ (0.34)	$ (0.6)

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 3,808,633	$ 978,741	$ 1,989,462	$ 5,791,562

Trade Accounts Receivable (Deta

Trade Accounts Receivable (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Trade Accounts Receivable [Line Items]
Trade accounts receivable, net	$ 2,307,913	$ 2,185,383
Related Party [Member]
Trade Accounts Receivable [Line Items]
Trade accounts receivable, net	$ 35,364	$ 42,507

Inventory (Details)

Inventory (Details) - USD ($)	9 Months Ended	12 Months Ended
Inventory (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Inventory [Abstract]
Inventory write off	$ 368,723	$ 527,133

Inventory (Details) - Schedule

Inventory (Details) - Schedule of Inventory - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Schedule of Inventory [Abstract]
Raw materials	$ 1,313,766	$ 1,594,028
Work-in-process	6,124,394	5,815,194
Finished goods	22,292	402,619
Total	$ 7,460,452	$ 7,811,841

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Schedule of Prepaid Expenses and Other Current Assets [Abstract]
Prepaid expenses	$ 277,146	$ 454,152
Other receivables	33,342	39,733
Total	$ 310,488	$ 493,885

Property, Plant and Equipment_3

Property, Plant and Equipment, Net (Details) - USD ($)	3 Months Ended		9 Months Ended
Property, Plant and Equipment, Net (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Property, Plant and Equipment, Net [Abstract]
Property, plant and equipment disposals	$ 49,652	$ 43,503	$ 120,814	$ 100,142
Depreciation expense	$ 670,346	$ 695,635	$ 1,999,005	$ 2,027,788

Property, Plant and Equipment_4

Property, Plant and Equipment, Net (Details) - Schedule of Property, Plant and Equipment - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Schedule of Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 46,201,529	$ 46,059,631
Accumulated depreciation	(20,381,196)	(18,483,948)
Property, plant and equipment, net	25,820,333	27,575,683
Laboratory and manufacturing equipment [Member]
Schedule of Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	21,183,888	20,953,601
Buildings and improvements [Member]
Schedule of Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	20,858,708	20,784,565
Office furniture and equipment [Member]
Schedule of Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,053,436	1,036,374
Construction in progress [Member]
Schedule of Property, Plant and Equipment [Line Items]
Property, plant and equipment, Estimated Useful Lives (in years)
Property, plant and equipment, gross	$ 2,588,630	2,768,224
Land [Member]
Schedule of Property, Plant and Equipment [Line Items]
Property, plant and equipment, Estimated Useful Lives (in years)
Property, plant and equipment, gross	$ 516,867	$ 516,867
Minimum [Member] \| Laboratory and manufacturing equipment [Member]
Schedule of Property, Plant and Equipment [Line Items]
Property, plant and equipment, Estimated Useful Lives (in years)	3 years
Minimum [Member] \| Buildings and improvements [Member]
Schedule of Property, Plant and Equipment [Line Items]
Property, plant and equipment, Estimated Useful Lives (in years)	10 years
Minimum [Member] \| Office furniture and equipment [Member]
Schedule of Property, Plant and Equipment [Line Items]
Property, plant and equipment, Estimated Useful Lives (in years)	3 years
Maximum [Member] \| Laboratory and manufacturing equipment [Member]
Schedule of Property, Plant and Equipment [Line Items]
Property, plant and equipment, Estimated Useful Lives (in years)	10 years
Maximum [Member] \| Buildings and improvements [Member]
Schedule of Property, Plant and Equipment [Line Items]
Property, plant and equipment, Estimated Useful Lives (in years)	39 years
Maximum [Member] \| Office furniture and equipment [Member]
Schedule of Property, Plant and Equipment [Line Items]
Property, plant and equipment, Estimated Useful Lives (in years)	10 years

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Intangible Assets (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2025	Dec. 31, 2023
Intangible Assets [Line Items]
Intangible assets	$ 191,040		$ 191,040			$ 191,040
Intangible asset amortized, useful lives	10 years		10 years
Intangible amortization expense	$ 4,776	$ 4,776	$ 14,328	$ 14,328
Net value	$ 23,880		$ 23,880			$ 38,208
Forecast [Member]
Intangible Assets [Line Items]
Intangible amortization expense					$ 19,104

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of Intangible Assets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Schedule of Intangible Assets [Line Items]
Gross Carrying Value	$ 191,040	$ 191,040
Accumulated Amortization	(167,160)	(152,832)
Net Book Value	23,880	38,208
Developed technology [Member]
Schedule of Intangible Assets [Line Items]
Gross Carrying Value	184,100	184,100
Accumulated Amortization	(161,087)	(147,280)
Net Book Value	23,013	36,820
Customer relationships [Member]
Schedule of Intangible Assets [Line Items]
Gross Carrying Value	1,300	1,300
Accumulated Amortization	(1,138)	(1,040)
Net Book Value	162	260
Non-compete agreements [Member]
Schedule of Intangible Assets [Line Items]
Gross Carrying Value	5,640	5,640
Accumulated Amortization	(4,935)	(4,512)
Net Book Value	$ 705	$ 1,128

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Schedule of Accounts Payable and Accrued Expenses [Abstract]
Accounts payable – trade	$ 876,836	$ 874,558
Accounts payable – capital	6,378	13,175
Accrued payroll	1,142,318	942,999
Accrued professional fees	101,725	97,800
Accrued other	376,112	192,754
Income tax payable	1,166	3,051
Total	$ 2,504,535	$ 2,124,337

Bank Debt (Details)

Bank Debt (Details)			3 Months Ended	6 Months Ended	9 Months Ended			12 Months Ended
Bank Debt (Details)	Sep. 30, 2027	Jun. 30, 2021 USD ($)	Mar. 31, 2020 USD ($)	Jun. 30, 2024	Sep. 30, 2026 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2025	Dec. 31, 2020 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2020 USD ($)
Bank Debt [Line Items]
Bearing interest percentage						3.53%				3.58%
Mortgage debt										$ 2,000,000
Line of credit			$ 1,000,000			$ 1,000,000
Debt issuance costs						173,305
Incurred costs						5,037	$ 0
Gorham Savings Bank [Member]
Bank Debt [Line Items]
Debt financing			8,600,000
Bank Loans [Member]
Bank Debt [Line Items]
Line of credit						1,000,000
Minimum [Member]
Bank Debt [Line Items]
Balloon principal payment						3,145,888
Outstanding principal balance						4,233,957
Maximum [Member]
Bank Debt [Line Items]
Balloon principal payment						3,687,577
Outstanding principal balance						$ 6,233,957
Loan #1 [Member]
Bank Debt [Line Items]
Balloon principal payment			3,145,888
Loan #1 [Member] \| Gorham Savings Bank [Member]
Bank Debt [Line Items]
Escrow account			$ 5,100,000
Bearing interest percentage			3.50%
Interest payments, term			10 years
Loan #2 [Member]
Bank Debt [Line Items]
Bearing interest percentage			3.50%
Balloon principal payment			$ 3,500,000
Loan #3 [Member] \| Maine Technology Institute [Member]
Bank Debt [Line Items]
Principal payment											$ 500,000
Loan amortization, term				2 years 3 months
Loans #4 [Member] \| Gorham Savings Bank [Member]
Bank Debt [Line Items]
Debt financing									$ 1,500,000
Bearing interest percentage									3.50%
Loan amortization, term									7 years
Loan #6 [Member]
Bank Debt [Line Items]
Debt financing							$ 2,000,000
Bearing interest percentage							7%
Finance loan provided							$ 1,000,000
Loan #6 [Member] \| Maine Technology Institute [Member]
Bank Debt [Line Items]
Debt financing									$ 1,400,000
Proceeds from issuance of loan									$ 624,167
Loan to value ratio									80%
Loan #5 [Member]
Bank Debt [Line Items]
Principal payment		$ 400,000
Interest fixed rate		5%
Loan #5 [Member] \| Gorham Savings Bank [Member]
Bank Debt [Line Items]
Loan amortization, term		5 years 6 months
Loan #7 [Member]
Bank Debt [Line Items]
Debt financing							$ 1,000,000
Bearing interest percentage							8%
Forecast [Member]
Bank Debt [Line Items]
Balloon principal payment					$ 649,631
DSC ratio								1.35
Forecast [Member] \| Maine Technology Institute [Member]
Bank Debt [Line Items]
Loan amortization, term	5 years
Forecast [Member] \| Loan #3 [Member]
Bank Debt [Line Items]
Interest fixed rate	5%
Forecast [Member] \| Loan #6 [Member]
Bank Debt [Line Items]
Balloon principal payment					$ 1,285,056
Forecast [Member] \| Loan #6 [Member] \| Mortgage Note [Member]
Bank Debt [Line Items]
Loan amortization, term					7 years
Forecast [Member] \| Loan #7 [Member]
Bank Debt [Line Items]
Loan amortization, term					7 years

Bank Debt (Details) - Schedule

Bank Debt (Details) - Schedule of Debt Proceeds Received and Principal Repayments - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Debt Proceeds Received and Principal Repayments [Line Items]
Proceeds from Debt Issuance		$ 3,000,000		$ 3,000,000	$ 3,000,000	$ 2,000,000
Debt Principal Repayments	368,249	325,737	1,094,106	829,015	1,185,774	897,125
Loan #1 [Member]
Schedule of Debt Proceeds Received and Principal Repayments [Line Items]
Proceeds from Debt Issuance						2,000,000
Debt Principal Repayments	57,671	55,619	172,017	166,527	223,222	199,013
Loan #2 [Member]
Schedule of Debt Proceeds Received and Principal Repayments [Line Items]
Proceeds from Debt Issuance
Debt Principal Repayments	128,534	124,020	382,324	369,154	494,455	477,237
Loan #3 [Member]
Schedule of Debt Proceeds Received and Principal Repayments [Line Items]
Proceeds from Debt Issuance
Debt Principal Repayments	24,173	23,002	71,629	68,156	91,446	22,160
Loan #4 [Member]
Schedule of Debt Proceeds Received and Principal Repayments [Line Items]
Proceeds from Debt Issuance
Debt Principal Repayments	53,505	51,622	159,171	153,704	205,884	198,715
Loan #5 [Member]
Schedule of Debt Proceeds Received and Principal Repayments [Line Items]
Proceeds from Debt Issuance
Debt Principal Repayments	16,719	15,909	49,542	15,909	32,017
Loan #6 [Member]
Schedule of Debt Proceeds Received and Principal Repayments [Line Items]
Proceeds from Debt Issuance		2,000,000		2,000,000	2,000,000
Debt Principal Repayments	59,191	36,582	174,804	36,582	93,054
Loan #7 [Member]
Schedule of Debt Proceeds Received and Principal Repayments [Line Items]
Proceeds from Debt Issuance		1,000,000		1,000,000	1,000,000
Debt Principal Repayments	$ 28,456	$ 18,983	$ 84,619	$ 18,983	$ 45,696

Bank Debt (Details) - Schedul_2

Bank Debt (Details) - Schedule of Principal Payments Bank Loans Outstanding	Sep. 30, 2024 USD ($)
Schedule of Principal Payments Bank Loans Outstanding [Line Items]
Debt issuance costs During the Three-Month Period Ending December 31, 2024	$ (5,583)
Debt issuance costs 2025	(21,314)
Debt issuance costs 2026	(13,580)
Debt issuance costs 2027	(5,420)
Debt issuance costs 2028	(3,513)
Debt issuance costs Thereafter	(11,347)
Debt issuance costs, Total	(60,757)
Debt discount cost During the Three-Month Period Ending December 31, 2024	(5,223)
Debt discount cost 2025	(20,891)
Debt discount cost 2026	(11,344)
Debt discount cost 2027
Debt discount cost 2028
Debt discount cost Thereafter
Debt discount cost Total	(37,458)
Total During the Three-Month Period Ending December 31, 2024	363,418
Total 2025	1,497,626
Total 2026	3,316,349
Total 2027	793,406
Total 2028	344,110
Total Thereafter	4,587,110
Total	10,902,019
Loan #1 [Member]
Schedule of Principal Payments Bank Loans Outstanding [Line Items]
During the Three-Month Period Ending December 31, 2024	58,765
During the Three-Month Period Ending December 31, 2025	239,876
During the Three-Month Period Ending December 31, 2026	248,604
During the Three-Month Period Ending December 31, 2027	257,649
During the Three-Month Period Ending December 31, 2028	266,537
During the Three-Month Period Ending ,Thereafter	4,598,457
During the Three-Month Period Ending, Total	5,669,888
Loan #2 [Member]
Schedule of Principal Payments Bank Loans Outstanding [Line Items]
During the Three-Month Period Ending December 31, 2024	129,801
During the Three-Month Period Ending December 31, 2025	530,738
During the Three-Month Period Ending December 31, 2026	549,881
During the Three-Month Period Ending December 31, 2027	140,436
During the Three-Month Period Ending December 31, 2028
During the Three-Month Period Ending ,Thereafter
During the Three-Month Period Ending, Total	1,350,856
Loan #3 [Member]
Schedule of Principal Payments Bank Loans Outstanding [Line Items]
During the Three-Month Period Ending December 31, 2024	24,476
During the Three-Month Period Ending December 31, 2025	101,000
During the Three-Month Period Ending December 31, 2026	106,146
During the Three-Month Period Ending December 31, 2027	83,143
During the Three-Month Period Ending December 31, 2028
During the Three-Month Period Ending ,Thereafter
During the Three-Month Period Ending, Total	314,765
Loan #4 [Member]
Schedule of Principal Payments Bank Loans Outstanding [Line Items]
During the Three-Month Period Ending December 31, 2024	54,055
During the Three-Month Period Ending December 31, 2025	220,994
During the Three-Month Period Ending December 31, 2026	228,965
During the Three-Month Period Ending December 31, 2027	240,442
During the Three-Month Period Ending December 31, 2028
During the Three-Month Period Ending ,Thereafter
During the Three-Month Period Ending, Total	744,456
Loan #5 [Member]
Schedule of Principal Payments Bank Loans Outstanding [Line Items]
During the Three-Month Period Ending December 31, 2024	16,929
During the Three-Month Period Ending December 31, 2025	69,856
During the Three-Month Period Ending December 31, 2026	73,415
During the Three-Month Period Ending December 31, 2027	77,156
During the Three-Month Period Ending December 31, 2028	81,086
During the Three-Month Period Ending ,Thereafter
During the Three-Month Period Ending, Total	318,442
Loan #6 [Member]
Schedule of Principal Payments Bank Loans Outstanding [Line Items]
During the Three-Month Period Ending December 31, 2024	60,581
During the Three-Month Period Ending December 31, 2025	253,003
During the Three-Month Period Ending December 31, 2026	1,418,558
During the Three-Month Period Ending December 31, 2027
During the Three-Month Period Ending December 31, 2028
During the Three-Month Period Ending ,Thereafter
During the Three-Month Period Ending, Total	1,732,142
Loan #7 [Member]
Schedule of Principal Payments Bank Loans Outstanding [Line Items]
During the Three-Month Period Ending December 31, 2024	29,617
During the Three-Month Period Ending December 31, 2025	124,364
During the Three-Month Period Ending December 31, 2026	715,704
During the Three-Month Period Ending December 31, 2027
During the Three-Month Period Ending December 31, 2028
During the Three-Month Period Ending ,Thereafter
During the Three-Month Period Ending, Total	869,685
Subtotal [Member]
Schedule of Principal Payments Bank Loans Outstanding [Line Items]
During the Three-Month Period Ending December 31, 2024	374,224
During the Three-Month Period Ending December 31, 2025	1,539,831
During the Three-Month Period Ending December 31, 2026	3,341,273
During the Three-Month Period Ending December 31, 2027	798,826
During the Three-Month Period Ending December 31, 2028	347,623
During the Three-Month Period Ending ,Thereafter	4,598,457
During the Three-Month Period Ending, Total	$ 11,000,234

Contingent Liabilities and Co_2

Contingent Liabilities and Commitments (Details) - USD ($)	3 Months Ended	9 Months Ended
Contingent Liabilities and Commitments (Details) - USD ($)	Mar. 31, 2022	Sep. 30, 2024	Jan. 01, 2024	Dec. 31, 2023	Jan. 01, 2023
Contingent Liabilities and Commitments [Line Items]
Total accrued amount	$ 222,379
Accounts payable and accrued expenses		$ 275,000		$ 200,000
Deferred compensation		300,000	$ 100,000		$ 100,000
Capital expenditures committed		186,000
Purchase of inventory		1,818,000
Commitments related to information technology services and other obligations		711,000
Re-Tain [Member]
Contingent Liabilities and Commitments [Line Items]
Commitments related to commercial manufacture		22,000
Mr. Brigham [Member]
Contingent Liabilities and Commitments [Line Items]
Accounts payable and accrued expenses		230,162		$ 230,162
Deferred compensation		$ 100,000
Deferred compensation agreement annual base salary percentage		100%

Operating Lease (Details)

Operating Lease (Details)	Jul. 31, 2025 USD ($)	Nov. 01, 2023 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2022 ft²	Sep. 12, 2019 ft²
Operating Leases [Line Items]
Square feet (in Square Feet) \| ft²						14,300
Operating lease right of use assets			$ 4,592,718	$ 4,571,149
Operating lease liability			$ 4,630,648
Building [Member]
Operating Leases [Line Items]
Square feet (in Square Feet) \| ft²					15,400
Lease term			10 years		20 years
Renew term			10 years
Additional rent payment		$ 20,000
Operating lease right of use assets			$ 4,592,718	4,571,149
Operating lease liability			$ 4,630,648	$ 4,721,385
Forecast [Member] \| Building [Member]
Operating Leases [Line Items]
Additional rent payment	$ 248,743

Operating Lease (Details) - Sch

Operating Lease (Details) - Schedule of Lease Costs and Other Lease Information - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Lease Cost
Operating lease cost	$ 106,880	$ 98,714	$ 320,639	$ 244,954
Variable lease cost	21,486	9,720	50,638	27,054
Total lease cost	128,366	108,434	371,277	272,008
Operating Lease
Cash paid for operating lease liabilities	$ 144,315	$ 69,742	$ 432,945	$ 131,476
Weighted average remaining lease term (in years)	18 years 3 months 18 days	19 years 3 months 18 days	18 years 3 months 18 days	19 years 3 months 18 days
Weighted average discount rate	6.60%	6.30%	6.60%	6.30%

Operating Lease (Details) - S_2

Operating Lease (Details) - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases	Sep. 30, 2024 USD ($)
Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases [Abstract]
During the three-month period ending December 31, 2024	$ 144,315
During the years ending December 31,
2025	711,623
2026	349,744
2027	356,732
2028	363,870
Thereafter	5,949,488
Total lease payments (undiscounted cash flows)	7,875,772
Less: imputed interest (discount effect of cash flows)	(3,245,124)
Total operating liabilities	$ 4,630,648

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)		1 Months Ended						3 Months Ended		9 Months Ended		12 Months Ended	63 Months Ended
Stockholders’ Equity (Details) - USD ($)	Apr. 09, 2024	Apr. 30, 2021	Mar. 31, 2019	Dec. 31, 2017	Jul. 31, 2017	Oct. 31, 2016	Feb. 29, 2016	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Apr. 30, 2021	Dec. 31, 2022	Jun. 30, 2022	Jun. 10, 2020	Jun. 14, 2018
Stockholders’ Equity [Line Items]
Common stock shares sold		515,156	1,636,364	417,807	200,000		1,123,810
Gross proceeds (in Dollars)		$ 4,250,038	$ 9,000,002	$ 3,049,991	$ 1,050,000		$ 5,900,003			$ 3,833,090
Sale of stock, per share (in Dollars per share)		$ 8.25	$ 5.5	$ 7.3	$ 5.25		$ 5.25						$ 8.25
Net proceeds (in Dollars)		$ 4,233,026	$ 8,303,436	$ 2,734,173	$ 1,034,164		$ 5,313,224
Common stock, shares authorized	11,000,000							15,000,000		15,000,000		15,000,000
Legal, accounting and other fees amount (in Dollars)	$ 152,272
Shares sold under at-the-market offering										1,082,233
Stock options exercised during period								0		0
Exercise price (in Dollars per share)								$ 6.49	$ 5.19	$ 6.49	$ 5.19	$ 6.82		$ 7.19
Stock options granted										73,000	108,000
Stock-based compensation related to non-vested stock options (in Dollars)								$ 433,317		$ 433,317
Weighted-average period										1 year
Stock options granted during period
Common stock purchase price (in Dollars per share)										$ 70
Exercisable and transferable, description										The Rights (as amended) become exercisable and transferable apart from the common stock upon the earlier of i) 10 days following a public announcement that a person or group (Acquiring Person) has, without the prior consent of the Continuing Directors (as such term is defined in the Rights Agreement), acquired beneficial ownership of 20% or more of the outstanding common stock or ii) 10 days following commencement of a tender offer or exchange offer the consummation of which would result in ownership by a person or group of 20% or more of the outstanding common stock (the earlier of such dates being called the Distribution Date).
Purchase price (in Dollars per share)										$ 70
Common stock were changed percentage										50%
Price per Right (in Dollars per share)										$ 0.005
Extend the rights plan, description										Our Board of Directors decided to seek an advisory vote by stockholders at the Annual Meeting of Stockholders held in June of 2022, as to whether to extend the Rights Plan by one year to September 19, 2023. Of the votes actually cast on this proposal, 65% voted in favor, 32% voted against and 3% abstained. On the basis of this vote, our Board of Directors voted to extend the Rights Plan by one year to September 19, 2023. Our Board of Directors decided to seek another advisory vote by stockholders at the Annual Meeting of Stockholders held in June of 2023, as to whether to extend the Rights Plan by another year to September 19, 2024. Of the votes actually cast on this proposal, 65.10% voted in favor, 34.60% voted against and 0.30% abstained. On the basis of this vote, our Board of Directors voted to extend the Rights Plan by one year to September 19, 2024. Recognizing that there might be a substantial number of broker non-votes, our Board of Directors disclosed that it would be guided by the votes actually cast on these proposals in deciding whether to extend the expiration date of such plan by one year.
Common Stock Issuances [Member]
Stockholders’ Equity [Line Items]
Issuance and sale (in Dollars)	$ 20,000,000
Minimum [Member]
Stockholders’ Equity [Line Items]
Common stock, shares authorized																11,000,000	8,000,000
Percentage of acquiring person								20%		20%
Maximum [Member]
Stockholders’ Equity [Line Items]
Common stock, shares authorized																15,000,000	11,000,000
Percentage of acquiring person								20%		20%
Common Stock [Member]
Stockholders’ Equity [Line Items]
Shares sold under at-the-market offering								1,000,017		1,082,233
2010 Plan [Member]
Stockholders’ Equity [Line Items]
Common stock reserved for future issuance								300,000		300,000
Stock option expiration period										10 years
Options outstanding								183,500		183,500		188,500
Weighted average remaining life of options outstanding										5 years
Weighted average remaining life of the options exercisable										2 years
2010 Plan [Member] \| Minimum [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)								$ 3.6		$ 3.6
2010 Plan [Member] \| Maximum [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)								$ 10.04		$ 10.04
2017 Plan [Member]
Stockholders’ Equity [Line Items]
Stock option expiration period										10 years
Options outstanding								477,500		477,500		430,000
2017 Plan [Member] \| Minimum [Member]
Stockholders’ Equity [Line Items]
Common stock reserved for future issuance															300,000
2017 Plan [Member] \| Maximum [Member]
Stockholders’ Equity [Line Items]
Common stock reserved for future issuance															650,000
2017 Plan [Member] \| Common Stock [Member]
Stockholders’ Equity [Line Items]
Common stock reserved for future issuance								300,000		300,000
Employee Stock Option [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)								$ 3.8		$ 3.8
Acquiring Person [Member]
Stockholders’ Equity [Line Items]
Acquisition percentage								50%		50%
Employee Stock Option [Member]
Stockholders’ Equity [Line Items]
Stock options granted (in Dollars per share)										$ 1.72		$ 2.8
ATM Agreement [Member]
Stockholders’ Equity [Line Items]
Gross proceeds (in Dollars)										$ 3,833,090
Sales commissions (in Dollars)										$ 123,368
Common Stock [Member]
Stockholders’ Equity [Line Items]
Common stock shares sold													4,553,017
Gross proceeds (in Dollars)													$ 26,714,403
Weighted average price (in Dollars per share)		$ 5.87											$ 5.87
Private Placement [Member]
Stockholders’ Equity [Line Items]
Common stock shares sold						659,880
Gross proceeds (in Dollars)						$ 3,464,370
Sale of stock, per share (in Dollars per share)						$ 5.25
Net proceeds (in Dollars)						$ 3,160,923

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - Schedule of Activity Under the Stock Option Plans - USD ($)		3 Months Ended		9 Months Ended	12 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Dec. 31, 2023
Schedule of Activity Under the Stock Option Plans [Line Items]
Weighted Average Exercise Price, Outstanding, Beginning balance (in Dollars)	[1]			$ (1,071,121)	$ (661,310)
Aggregate Intrinsic Value, Outstanding, Beginning balance (in Dollars per share)				$ 6.82	$ 7.19
Weighted Average Exercise Price, Outstanding, Ending balance (in Dollars)	[1]	$ (1,891,421)		$ (1,891,421)	$ (1,071,121)
Aggregate Intrinsic Value, Outstanding, Ending balance (in Dollars per share)		$ 6.49	$ 5.19	$ 6.49	$ 6.82
Weighted Average Exercise Price, Vested (in Dollars per share)		$ 6.97		$ 6.97
Aggregate Intrinsic Value, Vested (in Dollars)	[1]	$ (1,068,740)		$ (1,068,740)
Weighted Average Exercise Price, Vested and expected to vest (in Dollars)	[1]	$ (1,891,421)		$ (1,891,421)
Aggregate Intrinsic Value, Vested and expected to vest (in Dollars per share)		$ 6.49		$ 6.49
Grants
Weighted Average Exercise Price, Grants (in Dollars per share)				3.8	5.16
Weighted Average Exercise Price, Terminations/forfeitures (in Dollars per share)	[2]			$ 6.75	7.12
Exercises		0		0
Weighted Average Exercise Price, Exercises (in Dollars per share)					$ 4.69
2010 Plan [Member]
Schedule of Activity Under the Stock Option Plans [Line Items]
Outstanding, Beginning balance				188,500	202,500
Outstanding, Ending balance		183,500		183,500	188,500
Vested		183,500		183,500
Vested and expected to vest		183,500		183,500
Reserved for future grants
Grants
Terminations/forfeitures	[2]			(5,000)	(10,000)
Exercises					(4,000)
2017 Plan [Member]
Schedule of Activity Under the Stock Option Plans [Line Items]
Outstanding, Beginning balance				430,000	402,500
Outstanding, Ending balance		477,500		477,500	430,000
Vested		136,500		136,500
Vested and expected to vest		477,500		477,500
Reserved for future grants		154,500		154,500
Grants				73,000	122,000
Terminations/forfeitures	[2]			(25,500)	(94,500)
Exercises

[1]Intrinsic value is the difference between the fair market value of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise price).[2]Terminations and forfeitures are recognized when they occur.

Stockholders_ Equity (Details_2

Stockholders’ Equity (Details) - Schedule of Additional Information About the Stock Option Plans - Stock Option [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Stockholders’ Equity (Details) - Schedule of Additional Information About the Stock Option Plans [Line Items]
Number of Shares, Non-vested stock options as of beginning balance (in Shares) \| shares	337,500
Weighted Average Fair Value at Grant Date, Non-vested stock options as of beginning balance	$ 3.66
Weighted Average Exercise Price, Non-vested stock options as of beginning balance	$ 7.14
Number of Shares, Non-vested stock options as of ending balance (in Shares) \| shares	341,000
Weighted Average Fair Value at Grant Date, Non-vested stock options as of ending balance	$ 3.14
Weighted Average Exercise Price, Non-vested stock options as of ending balance	$ 6.04
Number of Shares, Stock options granted (in Shares) \| shares	73,000
Weighted Average Fair Value at Grant Date, Stock options granted	$ 1.72
Weighted Average Exercise Price, Stock options granted	$ 3.8
Number of Shares, Stock options that vested (in Shares) \| shares	54,000
Weighted Average Fair Value at Grant Date, Stock options that vested	$ 4.31
Weighted Average Exercise Price, Stock options that vested	$ 9.73
Number of Shares, Stock options that were forfeited (in Shares) \| shares	30,500
Weighted Average Fair Value at Grant Date, Stock options that were forfeited	$ 3.36
Weighted Average Exercise Price, Stock options that were forfeited	$ 6.75

Stockholders_ Equity (Details_3

Stockholders’ Equity (Details) - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions		3 Months Ended			9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023		Sep. 30, 2024	Sep. 30, 2023
Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions [Abstract]
Risk-free interest rate	[1]	3.48%		[2]	3.70%	3.48%
Dividend yield	[3]	0%	0%		0%	0%
Expected volatility	[3]	52%		[2]	51%	54%
Expected life	[4]	4 years 1 month 6 days		[2]	4 years 3 months 18 days	6 years 2 months 12 days

[1]The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected option term.[2]These values are not applicable because no

Revenue (Details) - Schedule of

Revenue (Details) - Schedule of Product Sales Disaggregated by Geographic Area - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Product Sales Disaggregated by Geographic Area [Line Items]
Total product Sales	$ 6,011,573	$ 5,396,500	$ 18,742,040	$ 12,375,708	$ 17,471,669	$ 18,567,962
Percentage of product sales	100%	100%	100%	100%
United States [Member]
Schedule of Product Sales Disaggregated by Geographic Area [Line Items]
Total product Sales	$ 5,216,401	$ 4,923,265	$ 16,449,178	$ 11,173,686
Percentage of product sales	87%	91%	88%	90%
Other [Member]
Schedule of Product Sales Disaggregated by Geographic Area [Line Items]
Total product Sales	$ 795,172	$ 473,235	$ 2,292,862	$ 1,202,022
Percentage of product sales	13%	9%	12%	10%

Revenue (Details) - Schedule _2

Revenue (Details) - Schedule of Product Sales Disaggregated by Major Product Category - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Product Sales Disaggregated by Major Product Category [Line Items]
Total product sales	$ 6,011,573	$ 5,396,500	$ 18,742,040	$ 12,375,708	$ 17,471,669	$ 18,567,962
Percentage of product sales	100%	100%	100%	100%
First Defense® product line [Member]
Schedule of Product Sales Disaggregated by Major Product Category [Line Items]
Total product sales	$ 5,951,344	$ 5,360,063	$ 18,602,053	$ 12,253,555
Percentage of product sales	99%	99%	99%	99%
Other animal health [Member]
Schedule of Product Sales Disaggregated by Major Product Category [Line Items]
Total product sales	$ 60,229	$ 36,437	$ 139,987	$ 122,153
Percentage of product sales	1%	1%	1%	1%

Other Expenses, Net (Details)

Other Expenses, Net (Details) - USD ($)	3 Months Ended		9 Months Ended
Other Expenses, Net (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Other Expenses, Net [Abstract]
Amortization of debt issuance costs	$ 10,805	$ 8,687	$ 31,859	$ 12,525

Other Expenses, Net (Details) -

Other Expenses, Net (Details) - Schedule of Other Expenses Net - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Schedule of Other Expenses Net [Abstract]
Interest expense	[1]	$ 144,141	$ 144,616	$ 432,529	$ 323,177
Loss (gain) on disposal of property, plant and equipment			(68)	14,557	8,099
Interest income		(18,685)	(23,696)	(41,476)	(79,134)
Insurance recoveries	[2]		(365,127)		(365,127)
Income - other					(107)
Other expenses (income), net		$ 125,456	$ (244,275)	$ 405,610	$ (113,092)

[1]Interest expense includes amortization of debt issuance and debt discount costs of $10,805 and $8,687 during the three-month periods ended September 30, 2024 or 2023, respectively, and $31,859 and $12,525 during the nine-month periods ended September 30, 2024 and 2023, respectively.[2] The income from insurance recoveries resulted from claim benefits paid to us under our business interruption policy related to product contamination losses and a recovery from a vendor’s policy related to an equipment malfunction.

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended
Income Taxes (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2018	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Income Taxes [Line Items]
Income tax expense	$ 1,340	$ 229		$ 4,020	$ 3,279
Loss income before income taxes, rate	1%			1%
Non-cash income tax expense			$ 563,252
Value of our deferred tax assets	$ 0			$ 0
Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards						$ 17,759,519
Net operating loss carryforwards not expire						16,047,612
Net operating loss carryforwards expire						1,711,907
Expiration term				expire in 2034 through 2037
State [Member]
Income Taxes [Line Items]
Net operating loss carryforwards expire						$ 4,681,644
Expiration term				expire in 2037 through 2038
Federal General Business [Member]
Income Taxes [Line Items]
Net operating loss carryforwards expire	726,474			$ 726,474
Expiration term				expire in 2028 through 2044
State Tax Credit [Member]
Income Taxes [Line Items]
Net operating loss carryforwards expire	$ 981,604			$ 981,604
Expiration term				expire in 2024 through 2042

Segment Information (Details)

Segment Information (Details)	9 Months Ended
Segment Information (Details)	Sep. 30, 2024
Segment Information [Abstract]
Reportable business segments	2

Segment Information (Details) -

Segment Information (Details) - Schedule of Segment Information - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Segment Information [Line Items]
Product sales	$ 6,011,573	$ 5,396,500	$ 18,742,040	$ 12,375,708	$ 17,471,669	$ 18,567,962
Costs of goods sold	4,428,019	4,129,619	13,632,642	9,764,164	13,602,385	10,919,183
Gross margin	1,583,554	1,266,881	5,109,398	2,611,544	3,869,284	7,648,779
Product development expense	786,136	1,118,489	3,079,189	3,328,397	4,394,852	4,493,872
Sales and marketing expenses	844,045	817,486	2,629,925	2,416,701	3,088,215	3,190,033
Administrative expenses	528,267	514,952	1,661,838	1,611,026	2,134,295	2,263,817
Operating expenses	2,158,448	2,450,927	7,370,952	7,356,124	9,617,362	9,947,722
NET OPERATING INCOME (LOSS)	(574,894)	(1,184,046)	(2,261,554)	(4,744,580)	(5,748,078)	(2,298,943)
Total Assets	44,448,873	44,545,022	44,448,873	44,545,022	43,808,102	44,860,649
Depreciation and amortization expense	685,927	709,098	2,045,192	2,054,641	2,739,620	2,495,241
Capital Expenditures	88,412	420,515	269,509	1,811,169	1,892,513	3,975,274
Scours [Member]
Schedule of Segment Information [Line Items]
Product sales	5,951,344	5,360,063	18,602,054	12,253,555	17,293,933	18,411,949
Costs of goods sold	4,364,950	4,095,164	13,487,348	9,652,292	13,453,514	10,754,189
Gross margin	1,586,394	1,264,899	5,114,706	2,601,263	3,840,419	7,657,760
Product development expense	59,140		154,233	2,543	11,103	66,346
Sales and marketing expenses	699,584	641,682	2,224,836	1,890,404	2,447,137	1,871,926
Administrative expenses
Operating expenses	758,724	641,682	2,379,069	1,892,947	2,458,240	1,938,272
NET OPERATING INCOME (LOSS)	827,670	623,217	2,735,637	708,316	1,382,179	5,719,488
Total Assets	23,672,583	24,119,683	23,672,583	24,119,683	24,735,413	20,539,523
Depreciation and amortization expense	346,430	355,673	1,027,711	1,020,909	1,365,988	1,169,011
Capital Expenditures	87,286	341,386	235,600	1,038,033	1,096,819	3,497,834
Mastitis [Member]
Schedule of Segment Information [Line Items]
Product sales	60,229	36,437	139,986	122,153	177,736	154,558
Costs of goods sold	63,069	34,455	145,294	111,872	148,871	136,347
Gross margin	(2,840)	1,982	(5,308)	10,281	28,865	18,211
Product development expense	690,052	1,082,346	2,821,525	3,220,075	4,242,329	4,317,921
Sales and marketing expenses	144,461	175,804	405,089	526,297	641,078	1,318,107
Administrative expenses
Operating expenses	834,513	1,258,150	3,226,614	3,746,372	4,883,407	5,636,028
NET OPERATING INCOME (LOSS)	(837,353)	(1,256,168)	(3,231,922)	(3,736,091)	(4,854,542)	(5,617,817)
Total Assets	16,798,955	18,132,922	16,798,955	18,132,922	17,827,839	18,315,492
Depreciation and amortization expense	319,815	328,381	958,260	969,666	1,287,600	1,263,318
Capital Expenditures	1,126	79,129	33,909	773,136	795,694	429,988
Other [Member]
Schedule of Segment Information [Line Items]
Product sales						1,455
Costs of goods sold						28,647
Gross margin						(27,192)
Product development expense	36,944	36,143	103,431	105,779	141,420	109,605
Sales and marketing expenses
Administrative expenses	528,267	514,952	1,661,838	1,611,026	2,134,295	2,263,817
Operating expenses	565,211	551,095	1,765,269	1,716,805	2,275,715	2,373,422
NET OPERATING INCOME (LOSS)	(565,211)	(551,095)	(1,765,269)	(1,716,805)	(2,275,715)	(2,400,614)
Total Assets	3,977,335	2,292,417	3,977,335	2,292,417	1,244,850	6,005,634
Depreciation and amortization expense	19,682	25,044	59,221	64,066	86,032	62,912
Capital Expenditures						$ 47,452

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	9 Months Ended
Related Party Transactions (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Related Party Transactions [Line Items]
Related party products purchased	$ 390,322	$ 128,521
Related Party [Member]
Related Party Transactions [Line Items]
Accounts receivable	$ 35,364		$ 42,507

Employee Benefits (Details)

Employee Benefits (Details) - USD ($)	3 Months Ended		9 Months Ended
Employee Benefits (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Employee Benefits [Line Items]
Employee’s salary percentage			100%
Employee’s salary contribution percentage			50%
Employee benefits paid	$ 55,989	$ 50,126	$ 159,504	$ 135,698
Employee [Member]
Employee Benefits [Line Items]
Employee’s salary percentage			3%
Employee One [Member]
Employee Benefits [Line Items]
Employee’s salary contribution percentage			2%

Subsequent Events (Details)

Subsequent Events (Details) - ATM Agreement [Member] - Subsequent Event [Member]	1 Months Ended
	Oct. 30, 2024 USD ($) shares
Subsequent Events [Line Items]
Shares sold during period \| shares	78,492
Gross proceeds from at-the-market offering \| $	$ 289,719